Combination of an SSAO inhibitor and a THR-beta agonist for use in the treatment of liver damage - Patents.com
A combination of SSAO/VAP-1 inhibitors and THR-β agonists, optionally with FXR agonists, effectively treats NASH by reducing inflammation and fibrosis, addressing the lack of approved therapies and side effects in current treatments.
Patent Information
- Application Number
- JP2024527519
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-07
- Filing Date
- 2022-11-11
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for nonalcoholic steatohepatitis (NASH) are burdensome, have dangerous side effects, and there are no approved therapies, making it a pressing need for effective and tolerable treatments.
Administering a combination of a semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) inhibitor and a thyroid hormone receptor beta (THR-β) agonist, optionally with a farnesoid X receptor (FXR) agonist, to treat liver disorders such as NASH.
The combination therapy reduces liver inflammation, fibrosis, and steatosis, potentially slowing the progression of NASH and improving liver health without significant adverse effects.
Smart Images

Figure 2024544528000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 263,933, filed November 11, 2021, and U.S. Provisional Patent Application No. 63 / 349,977, filed June 7, 2022. The contents of the above-referenced patent applications are incorporated herein by reference in their entirety for all purposes.
[0002] FIELD OF THEINVENTION The present invention relates to methods and compositions for treating liver damage in a patient. [Background technology]
[0003] Fatty liver disease (FLD) encompasses a variety of disease states characterized by excess accumulation of fat in the liver, often accompanied by inflammation. FLD can lead to nonalcoholic fatty liver disease (NAFLD), which may be characterized by insulin resistance. If untreated, NAFLD can progress to persistent inflammatory responses or nonalcoholic steatohepatitis (NASH), progressive liver fibrosis, and ultimately cirrhosis. In Europe and the West, NAFLD is the second most common cause of liver transplantation. Thus, the need for treatment is urgent, but because patients lack obvious symptoms, they may not be motivated to maintain treatment regimens, especially those that are burdensome, such as injectable drugs, drugs that are administered multiple times a day, or any that produce dangerous or irritating side effects. Currently, there is no approved treatment for NASH. Summary of the Invention
[0004] Provided herein are methods and compositions for treating liver disorders such as NASH in a patient in need of such treatment. The methods include administering to the patient a semicarbazide-sensitive amine oxidase (SSAO) / vascular adhesion protein-1 (VAP-1) inhibitor and a thyroid hormone receptor beta (THR-β) agonist as described herein. In some embodiments, the methods include administering to the patient a semicarbazide-sensitive amine oxidase (SSAO) / vascular adhesion protein-1 (VAP-1) inhibitor, a thyroid hormone receptor beta (THR-β) agonist, and a farnesoid X receptor (FXR) agonist as described herein.
[0005] In one aspect, the disclosure provides a method of reducing hepatitis in a patient in need of reduction, the method comprising administering to the patient a therapeutically effective amount of an SSAO inhibitor and a therapeutically effective amount of a THR-β agonist. In some embodiments, the disclosure provides a method of reducing hepatitis in a patient in need of reduction, the method comprising administering to the patient a therapeutically effective amount of an SSAO inhibitor, a therapeutically effective amount of a THR-β agonist, and an FXR agonist, as described herein.
[0006] In another aspect, the present disclosure provides a method for treating a disease or condition characterized by liver fibrosis, comprising administering to a patient a therapeutically effective amount of an SSAO inhibitor and a therapeutically effective amount of a THR-β agonist.In some embodiments, the present disclosure provides a method for treating a disease or condition characterized by liver fibrosis, comprising administering to a patient a therapeutically effective amount of an SSAO inhibitor, a therapeutically effective amount of a THR-β agonist, and an FXR agonist, as described herein.
[0007] In another aspect, the present disclosure provides a method for treating a disease or condition characterized by hepatic steatosis, the method comprising administering to a patient a therapeutically effective amount of an SSAO inhibitor and a therapeutically effective amount of a THR-β agonist. In some embodiments, the present disclosure provides a method for treating a disease or condition characterized by hepatic steatosis, the method comprising administering to a patient a therapeutically effective amount of an SSAO inhibitor, a therapeutically effective amount of a THR-β agonist, and an FXR agonist, as described herein.
[0008] In another aspect, the present disclosure provides a method for treating or preventing NASH in a patient in need of such treatment or prevention, comprising administering to the patient a therapeutically effective amount of an SSAO inhibitor and a therapeutically effective amount of a THR-β agonist.In some embodiments, the present disclosure provides a method for treating or preventing NASH in a patient in need of such treatment or prevention, comprising administering to the patient a therapeutically effective amount of an SSAO inhibitor, a therapeutically effective amount of a THR-β agonist, and an FXR agonist as described herein.In one embodiment, the patient in need of such treatment is a patient suffering from fatty liver disease, such as NAFLD.In another embodiment, the patient in need of such treatment is a patient suffering from metabolic syndrome.
[0009] In some embodiments, the SSAO inhibitor and the THR-β agonist, and optionally the FXR agonist, are administered simultaneously. In some such embodiments, the SSAO inhibitor and the THR-β agonist, and optionally the FXR agonist, are provided as a fixed dose composition in a single pharmaceutical composition as described herein. In other embodiments, the SSAO inhibitor and the THR-β agonist, and optionally the FXR agonist, are administered sequentially. In some embodiments, one or both of the SSAO inhibitor and the THR-β agonist are administered orally. In some embodiments, at least one of the SSAO inhibitor and the THR-β agonist, and the FXR agonist is administered orally.
[0010] In some embodiments, the patient has liver disease and diabetes. In some embodiments, the patient has liver disease and cardiovascular disease. In some embodiments, the duration of treatment is the remaining lifespan of the patient. In some embodiments, the method does not include administering an antihistamine, an immunosuppressant, a steroid, rifampicin, an opioid antagonist, or a selective serotonin reuptake inhibitor (SSRI).
[0011] In some embodiments, the SSAO inhibitor is administered once a day. In some embodiments, the SSAO inhibitor is administered twice a day. In some embodiments, the THR-β agonist is administered once a day. In some embodiments, the THR-β agonist is administered twice a day. In some embodiments, the FXR agonist is administered once a day. In some embodiments, the FXR agonist is administered twice a day. In some embodiments, the administration comprises administering the SSAO inhibitor daily for a treatment period of one week or more. In some embodiments, the administration comprises administering the THR-β agonist daily for a treatment period of one week or more. In some embodiments, the administration comprises administering the FXR agonist daily for a treatment period of one week or more. In some embodiments, the administration comprises administering the SSAO inhibitor daily and the THR-β agonist daily for a treatment period of one week or more. In some embodiments, the administration comprises administering the SSAO inhibitor daily, the THR-β agonist daily, and the FXR agonist daily for a treatment period of one week or more.
[0012] A variety of different SSAO inhibitors and THR-β agonists, and optionally FXR agonists, can be used to achieve the beneficial effects observed in liver diseases as described herein. For example, in some embodiments, the SSAO inhibitor administered to a patient in need of administration of an SSAO inhibitor is represented by formula (I): [ka] A compound of the formula n is 1 or 2; R1 is H or -CH 3 ), or a pharma- ceutically acceptable salt thereof.
[0013] In some embodiments, the SSAO inhibitor administered to a patient in need thereof is a compound of formula (I), where n is 1, or a pharma- ceutically acceptable salt thereof. In another embodiment, the SSAO inhibitor is a compound of formula (I), where n is 2, or a pharma- ceutically acceptable salt thereof.
[0014] In some embodiments, the SSAO inhibitor administered to a patient in need thereof is a compound of formula (I), wherein R1 is H, or a pharma- ceutically acceptable salt thereof. In yet another embodiment, the present invention provides a compound of formula (II), wherein R1 is -CH 3 or a pharma- ceutically acceptable salt thereof.
[0015] In some embodiments, the SSAO inhibitor administered to a patient in need thereof is [ka] (which is (E)-3-fluoro-2-(((2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl)oxy)methyl)prop-2-en-1-amine), or a pharma- ceutically acceptable salt thereof. In some embodiments, the SSAO inhibitor administered to the patient in need of administration of an SSAO inhibitor is (E)-3-fluoro-2-(((2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl)oxy)methyl)prop-2-en-1-amine dihydrochloride. In some embodiments, the SSAO inhibitor administered to the patient in need of administration of an SSAO inhibitor is (E)-3-fluoro-2-(((2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl)oxy)methyl)prop-2-en-1-amine 4-methylbenzenesulfonate.
[0016] In some embodiments, the THR-β agonist administered to the patient in need of administration of a THR-β agonist is resmetirom (MGL-3196). In some embodiments, the THR-β agonist VK2809 (by Viking Therapeutics) is administered to the patient in need thereof. In some embodiments, the THR-β agonist administered to the patient in need of administration of a THR-β agonist is sobetirom. In some embodiments, the THR-β agonist administered to the patient in need of administration of a THR-β agonist is eprotirom. In some embodiments, the THR-β agonist administered to the patient in need of administration of a THR-β agonist is ALG-055009 (by Aligo). In some embodiments, the THR-β agonist administered to the patient in need of administration of a THR-β agonist is CNPT-101101. In some embodiments, the THR-β agonist administered to a patient in need thereof is CNPT-101207. In some embodiments, the THR-β agonist administered to a patient in need thereof is ASC41 (by Ascletis).
[0017] In some embodiments, the THR-β agonist is represented by formula (II): [ka] A compound of the formula R 1 is hydrogen, cyano, substituted or unsubstituted C 1~6 Alkyl, and substituted or unsubstituted C 3~6 cycloalkyl, the substituents being halogen atoms, hydroxy, and C 1~6 alkoxy; R 2 and R 3 is a halogen atom and a substituted or unsubstituted C 1~6 alkyl, each independently selected from the group consisting of halogen, hydroxy, and C 1~6 alkoxy; Ring A is a substituted or unsubstituted saturated or unsaturated C 5~10 Aliphatic ring, or substituted or unsubstituted C 5~10 Aromatic ring with a substituent of hydrogen, halogen atom, hydroxyl, -OCF 3 , -NH 2 , -NHC 1~4 Alkyl, -N(C 1~4 Alkyl) 2 , -CONH 2 , -CONHC 1~4 Alkyl, -CON(C 1~4 Alkyl) 2 , -NHCOC 1~4 Alkyl, C 1~6 Alkyl, C 1~6 Alkoxy or C 3~6 one or more substances selected from the group consisting of cycloalkyl, where when two substituents are contained, the two substituents may form a ring structure together with the carbons to which they are attached; the halogen atoms are selected from the group consisting of F, Cl and Br; Or a pharma- ceutically acceptable salt thereof.
[0018] In some embodiments, the THR-β agonist administered to a patient in need thereof is a compound represented by formula (IIa): [ka] A compound of the formula R 1 ~R 3 is defined as detailed herein for formula (II), R 4 However, hydrogen, halogen atoms, hydroxyl, -OCF 3 , -NH 2 , -NHC 1~4 Alkyl, -N(C 1~4 Alkyl) 2 , -CONH 2 , -CONHC 1~4 Alkyl, -CON(C 1~4 Alkyl) 2 , -NHCOC 1~4 Alkyl, C1~6 Alkyl, C 1~6 Alkoxy and C 3~6 cycloalkyl; m is an integer ranging from 1 to 4; the halogen atoms are selected from the group consisting of F, Cl and Br; or a pharma- ceutically acceptable salt thereof.
[0019] In some embodiments, R 4 is hydrogen, halogen atom, hydroxy, -OCF 3 , C 1~6 Alkyl, C 1~6 Alkoxy and C 3~6 cycloalkyl, and m is an integer ranging from 1 to 3.
[0020] In some embodiments, R 1 is hydrogen, cyano, and substituted or unsubstituted C 1~6 alkyl, and the substituents are halogen atoms, hydroxy, and C 1~6 The alkoxy group is selected from the group consisting of halogen atoms, and the halogen atoms are selected from the group consisting of F, Cl and Br.
[0021] In some embodiments, the THR-β agonist is [ka] (which is 2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile), or a pharma- ceutically acceptable salt thereof. In some embodiments, the THR-β agonist is 2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile potassium salt. In some embodiments, the THR-β agonist is 2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile sodium salt.
[0022] In some embodiments, the FXR agonist is obeticholic acid. In some embodiments, the FXR agonist is cilofexor. In some embodiments, the FXR agonist is tropifexor. In some embodiments, the FXR agonist is EYP001 (Vonafexor, proposed INN). In some embodiments, the FXR agonist is MET409 (Metacrine). In some embodiments, the FXR agonist is EDP-305 (by Enanta).
[0023] In some embodiments, the FXR agonist has formula (III): [ka] A compound of the formula q is 1 or 2; R 1 is chloro, fluoro, or trifluoromethoxy; R 2 is hydrogen, chloro, fluoro, or trifluoromethoxy; R 3a is trifluoromethyl, cyclopropyl, or isopropyl; X is CH or N, with the proviso that when X is CH, q is 1; Ar 1 is indolyl, benzothienyl, naphthyl, phenyl, benzisothiazolyl, indazolyl, or pyridinyl, each of which is optionally substituted with methyl or phenyl; or a pharma- ceutically acceptable salt thereof.
[0024] In some embodiments, the FXR agonist is [ka] or a pharma- ceutically acceptable salt thereof.
[0025] In some embodiments, there is provided a method of treating liver injury in a patient in need of such treatment with a semicarbazide-sensitive amine oxidase (SSAO) inhibitor and a thyroid hormone receptor beta (THR-β) agonist, and optionally an FXR agonist, the method comprising administering a therapeutically effective amount of the SSAO inhibitor, wherein the SSAO inhibitor [ka] or a pharma- ceutical acceptable salt thereof, and administering a therapeutically effective amount of a THR-β agonist, [ka] or a pharma- ceutical acceptable salt thereof, and optionally administering a therapeutically effective amount of an FXR agonist, wherein the liver disorder is selected from liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). In some embodiments, the liver disorder is NASH.
[0026] In some embodiments, there is provided a method of treating liver injury in a patient in need of such treatment with a semicarbazide-sensitive amine oxidase (SSAO) inhibitor and a thyroid hormone receptor beta (THR-β) agonist, the method comprising administering a therapeutically effective amount of the SSAO inhibitor, [ka] or a pharma- ceutical acceptable salt thereof, and administering a therapeutically effective amount of a THR-β agonist, [ka] or a pharma- ceutically acceptable salt thereof, and optionally administering a therapeutically effective amount of an FXR agonist, wherein the FXR agonist is [ka] or a pharma- ceutically acceptable salt thereof, wherein the liver disorder is selected from liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). In some embodiments, the liver disorder is NASH.
[0027] In some embodiments, there is provided a method of treating liver injury in a patient in need thereof with a semicarbazide-sensitive amine oxidase (SSAO) inhibitor and a thyroid hormone receptor beta (THR-β) agonist, the method comprising administering a therapeutically effective amount of the SSAO inhibitor, wherein the SSAO inhibitor: [ka] and administering a therapeutically effective amount of a THR-β agonist, the THR-β agonist being [ka] and optionally administering a therapeutically effective amount of an FXR agonist, wherein the FXR agonist is [ka] and the liver disorder is selected from liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). In some embodiments, the liver disorder is NASH. [Brief description of the drawings]
[0028] [Figure 1A] Plasma SSAO-specific amine oxidase activity compared to baseline in healthy volunteers 4 and 168 hours after administration of a single dose of placebo or 1, 3, 6, or 10 mg of Compound 1 is shown. [Figure 1B] 1 shows the time course of plasma total amine oxidase activity compared to baseline in healthy volunteers administered a single dose of placebo or 1, 3, 6, or 10 mg of Compound 1. [Figure 1C] 1 shows the time course of Compound 1 levels following single doses of placebo or 1, 3, 6, or 10 mg in healthy volunteers. [Figure 1D] 1 shows the time course of plasma methylamine concentrations following a single dose of placebo or 1, 3, 6, or 10 mg of Compound 1 in healthy volunteers. [Diagram 2] A shows the time course of compound 1 concentrations after a single dose of 1, 4, or 10 mg of compound 1 in healthy volunteers, and B shows the time course of compound 1 concentrations on the final day of a 7-day treatment with 1 mg or 4 mg of compound 1 and on the final day of a 14-day treatment with 10 mg of compound 1. [Figure 3A] 1 shows SSAO-specific amine oxidase activity 24 hours after an initial daily dose of 1, 4, or 10 mg of Compound 1 in healthy volunteers. [Figure 3B] 1 shows the time course of plasma methylamine concentrations following an initial daily dose of 1, 4, or 10 mg of Compound 1 in healthy volunteers. [Figure 3C] 1 shows the time course of both plasma methylamine concentrations in healthy volunteers after the final day of a 7-day treatment with 1 mg or 4 mg of Compound 1, and after the final day of a 14-day treatment with 10 mg of Compound 1. [Figure 3D] 1 shows the time course of total amine oxidase activity (percent change from baseline) following a single dose of 1, 4, or 10 mg of Compound 1 in healthy volunteers. [Figure 3E] 1 shows the 14-day time course (percent change from baseline) of total amine oxidase activity in healthy volunteers after day 6 of a 7-day administration of 1 mg or 4 mg of Compound 1, or after day 13 of a 14-day administration of 10 mg of Compound 1.
[0029] [Figure 4] A shows the effect of Compound 2 on serum cholesterol in a rat hypercholesterolemia model.B shows the effect of Compound 2 on serum triglyceride in a rat hypercholesterolemia model. [Diagram 5] 1 shows the effect of Compound 2 on body and organ weights in a mouse NASH model. [Figure 6] FIG. 1 shows the effect of Compound 2 on hepatic steatosis, inflammation, and fibrosis in a mouse NASH model. [Figure 7] 1 shows the effect of Compound 2 on lipids and an index of liver damage (ALT) in a mouse NASH model. [Figure 8] FIG. 1 shows the effect of Compound 2 on the expression of genes associated with collagen extracellular matrix and hepatic stellate cell activation. [Figure 9] 1 shows plasma concentrations of Compound 2 in beagle dogs following administration of a 50 mg capsule of Compound 2 with or without 5 wt % SLS. [Figure 10]The plasma concentrations of Compound 2 in beagle dogs following pretreatment with pentagastrin or famotidine are compared. [Figure 11] Plasma concentrations of Compound 2 in beagle dogs under fasted or fed conditions are compared. [Figure 12] 1 shows heart rates in healthy human patients upon administration of a single dose of placebo or 3 mg, 10 mg, 30 mg, and 60 mg doses of Compound 2. [Figure 13] A shows the plasma concentration of Compound 2 in healthy humans after administration of 3 mg, 10 mg, 30 mg, and 60 mg doses of Compound 2. B correlates the AUC and Cmax to each dose. [Figure 14] A shows the percent change from baseline in sex hormone binding globulin (SHBG) after administration of a single dose of Compound 2 at 3 mg, 10 mg, 30 mg, and 60 mg doses. B shows the percent change from baseline in apolipoprotein B (ApoB) after administration of a single dose of Compound 2 at 3 mg, 10 mg, 30 mg, and 60 mg doses.
[0030] [Figure 15A] 1 shows free T3 on day 15 after 14 days of administration of Compound 2 or placebo in humans. [Figure 15B] 1 shows free T4 on day 15 after 14 days of administration of Compound 2 or placebo in humans. [Figure 15C] 1 shows TSH on day 15 after 14 days of administration of Compound 2 or placebo in humans. [Figure 16A] 1 shows the percent change in free testosterone from baseline on day 15 after 14 days of administration of Compound 2 or placebo in humans. [Figure 16B] 1 shows the percent change in total testosterone from baseline at day 15 following 14 days of administration of Compound 2 or placebo in humans. [Figure 16C]1 shows the percent change in sex hormone binding globulin (SHBG) from baseline on day 15 following 14 days of administration of Compound 2 or placebo in humans. [Figure 17] FIG. 1 shows the plasma concentration of Compound 2 over time on days 1 and 14 of a multiple ascending dose study where Compound 2 was administered once daily. [Figure 18] 1 shows the percent change from baseline in pharmacodynamic markers (sex hormone binding globulin, ApoB, total cholesterol, LDL-c, HDL-c, and triglycerides) on day 15 following 14 days of administration of Compound 2 or placebo in humans. [Figure 19] Figure 1 shows the levels of Treg and M2 macrophage liver infiltration as determined by single sample gene set enrichment analysis performed on liver RNA sequencing data from CDHFD rats administered NaNO2 and treated with compound 3, compound 1, or a combination of compound 3 and compound 1 (*p value < 0.05, ***p value < 0.001).
[0031] [Figure 20] Expression analysis of Treg and M2 macrophage markers by RNA sequencing in the liver of CDHFD rats administered NaNO2 and treated with compound 3, compound 1, or a combination of compound 3 and compound 1. Ikzf2, IKAROS family zinc finger 2 (Treg marker), Foxp3, forkhead box P3 (Treg marker), Cd163 (M2 macrophage marker). (*p value < 0.05, **p value < 0.01). [Figure 21] The number and overlap of differentially expressed genes (DEGs) identified by RNA sequencing analysis in livers of CDHFD rats administered NaNO2 and treated with Compound 3, Compound 1, or a combination of Compound 3 and Compound 1 are shown compared to vehicle NASH controls using fold change and p-value cutoffs of ≥1.5-fold and 0.01, respectively. [Figure 22]1 shows differential gene expression analysis of selected biological processes in a mouse model of NASH treated with 3 mg / kg Compound 3 and / or 1 mg / kg Compound 2. [Figure 23] The number and overlap of differentially expressed genes (DEGs) identified in mouse models of NASH treated with 3 mg / kg Compound 3, 1 mg / kg Compound 2, or 3 mg / kg Compound 3 and 1 mg / kg Compound 2 are shown compared to vehicle NASH controls. [Figure 24] The number and overlap of biological processes significantly enriched in mouse models of NASH treated with 3 mg / kg Compound 3, 1 mg / kg Compound 2, or 3 mg / kg Compound 3 and 1 mg / kg Compound 2 compared to vehicle NASH controls are shown. [Diagram 25] Serum triglycerides, total cholesterol, and alanine aminotransferase (ALT), as well as hepatic steatosis, inflammation, and fibrosis, are shown in mouse models of NASH treated with 3 mg / kg compound 3, 1 mg / kg compound 2, or 3 mg / kg compound 3 and 1 mg / kg compound 2 compared to vehicle NASH controls. [Figure 26] The expression levels of genes associated with the FXR and THRβ pathways in mouse models of NASH treated with 3 mg / kg compound 3, 1 mg / kg compound 2, or 3 mg / kg compound 3 and 1 mg / kg compound 2 are shown compared to vehicle NASH controls. [Figure 27] Average expression levels (count per million reads, CPM) of genes associated with fibrosis and inflammation pathways (determined by RNAseq) after treatment with a combination of Compound 3 and Compound 2. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 in mouse models of NASH versus vehicle (NASH) control. [Figure 28] The study design for Compound 1 is shown. [Figure 29] Patient demographics and baseline characteristics are shown.
[0032] [Diagram 30] Patient treatment according to study design is shown. [Diagram 31] A complete summary of adverse events is provided. [Figure 32A] TIMP-1 change from baseline to weeks 6 and 12 is shown. [Figure 32B] Results are shown for NASH and inflammatory biomarkers mean (SE) change from baseline to week 12. [Diagram 33] cT1 changes at 12 weeks are shown. [Diagram 34] VAP-1 / SSAO activity (%) at week 12 compared to baseline is shown. [Diagram 35] Changes in ELF components (TIMP-1, P3NP, HA) from baseline to week 12 are shown. [Diagram 36] Changes in ICAM-1 and VCAM-1 from baseline to week 12 are shown. [Figure 37] 1 shows a complete study of Compound 2 in healthy volunteers. [Figure 38] Patient demographics and baseline characteristics for Compound 2 are shown. [Figure 39] 1 shows the plasma concentration-time profile of Compound 2 on day 14.
[0033] [Diagram 40] PK parameters for Compound 2 at Day 14 are shown. [Diagram 41] Sex hormone binding globulin (SHBG) (percent change from baseline to day 15) is shown. [Diagram 42] LDL-c (percent change from baseline to day 15) is shown. [Diagram 43] 4 shows the percent change from baseline in SHBG and LDL-c at the end of treatment (day 15) by dose of Compound 2. [Diagram 44] Reduction in total cholesterol (TC), ApoB, and triglycerides (TG) per dose of Compound 2 is shown. [Diagram 45] Treatment-emergent adverse events were mild and largely non-relevant, indicating no significant changes in vital signs. [Diagram 46] Figure 1 shows biopsy-confirmed body weight change in male DIO-NASH mice. Compound 3 alone and in combination with Compound 2 reduced body weight. Body weight was measured daily during the study. In A, body weight change during the study is shown, with dots representing the mean body weight change compared to baseline (n=10-16 mice / group). In B, bars represent the mean (SD) body weight measured at week 11 of the study. Lean vehicle control: white, DIO-GAN vehicle control: grey, Compound 3: blue, Compound 2-low: light orange, Compound 2-medium: orange, Compound 2-high: dark orange, Combination-low: light purple, Combination-medium: purple, Combination-high: dark purple. Statistical comparisons to DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 47] Individual weekly food intake during the study is shown. Dots represent average weekly food intake (in grams) (n=10-16 mice / group). Lean vehicle control: white, DIO-GAN vehicle control: grey, Compound 3: blue, Compound 2-low: light orange, Compound 2-medium: orange, Compound 2-high: dark orange, Combination-low: light purple, Combination-medium: purple, Combination-high: dark purple.
[0034] [Figure 48] Liver and spleen weights are shown. Compound 3 and compound 2 alone, as well as their combination, significantly reduced hepatomegaly without changing spleen weight. Bars represent mean (SD) organ weights of liver (A) and spleen (B) determined at the end of the study (n=10-16 mice / group). Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 49]Body weight composition at baseline is shown. At baseline (week -1), body weight composition was well balanced across treatment groups. Bars represent mean (SD) adipose tissue (A) and lean tissue (B) mass as a percentage of body weight (%BW, n=10-16 mice / group) determined by whole-body EchoMRI at week -1 of the study. Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey's correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 50] Body weight composition at week 11 is shown. Compound 3 alone and in combination with compound 2 significantly reduced adipose tissue mass. Bars represent mean (SD) adipose tissue (A) and lean tissue (B) mass as a percentage of body weight (%BW, n=10-16 mice / group) determined by whole-body EchoMRI at week 11 of the study. Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 51] Plasma and liver total cholesterol are shown. Compound 3 and compound 2 alone and their combination significantly reduced total cholesterol. Bars represent mean (SD) total cholesterol levels (n=10-16 mice / group) measured at the end of the study in plasma (A) and liver (B). Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 52] Plasma and liver triglycerides are shown. Compound 3 alone and in combination with compound 2 significantly reduced plasma triglycerides. Bars represent mean (SD) triglyceride levels (n=10-16 mice / group) measured at the end of the study in plasma (A) and liver (B). Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey's correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0035] [Figure 53] Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are shown. Compound 2 alone significantly reduced alanine aminotransferase (ALT) levels. Bars represent mean (SD) ALT (A) and aspartate aminotransferase (AST) (B) levels (n=10-16 mice / group) determined at the end of the study. Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 54] Alkaline phosphatase levels are shown. Alkaline phosphatase (ALP) levels were not significantly altered by treatment. Bars represent mean (SD) ALP levels (n=10–16 mice / group) determined at the end of the study. Statistical comparisons to DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 55] NAFLD activity scores (NAS) at baseline and end of treatment are shown. NAFLD activity scores (NAS) were well balanced at baseline and significantly improved in the combination treatment group. NAS, defined as the composite unweighted sum of the histological scores of ballooning, steatosis, and lobular inflammation, was determined at baseline (A) and after 12 weeks of treatment (B). Points represent individual mice (n=14-16) within each treatment group. Statistical comparisons to DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0036] [Figure 56]Shows fatty liver by histological morphometric analysis. The combination of Compound 3 and Compound 2 resulted in a significant reduction in fatty liver as determined by histological morphometric analysis. Hepatocellular steatosis, including the percentage of hepatocytes containing lipid droplets and hepatic lipid content, was determined by morphometric analysis of liver histological samples at the end of the study as percent area fraction (FA). Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 57] Figure 1 shows lipid droplet size in hepatocytes. Combination treatment significantly reduces lipid droplet size in hepatocytes. Lipid droplet size was determined by morphometric analysis of liver histological samples at the end of the study. Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 58] Plasma CK18M30 is shown. The apoptosis biomarker cytokeratin 18M30 (CK18M30) levels were not significantly altered by treatment. The apoptosis biomarker CK18M30 was measured in plasma samples at the end of the study. Statistical comparisons to DIO-GAN vehicle control were determined by ANOVA followed by Tukey correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 59] Hepatic protein expression of galectin-3 and smooth muscle actin proteins are shown. Compound 3 treatment reduces the expression of galectin-3 (Gal-3). Expression of Gal-3 (A) and α-smooth muscle actin (α-SMA) (B) was assessed by immunohistochemistry (IHC) staining of livers of treated mice at the end of the study. Statistical comparisons with DIO-GAN vehicle control were determined by ANOVA followed by Tukey's correction for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 60]Figure 1 shows the expression of energy and lipid metabolism genes in liver. Comparison of gene expression values between Compound 2-High and Combination-High treatment groups for selected genes involved in energy and lipid metabolism. Liver samples were processed for transcriptomics analysis by RNAseq at termination. Points represent expression values of mean fold change (n=10 mice / group) compared to DIO-GAN vehicle control. Red and blue coloring indicates the direction of change (red=increased expression, blue=decreased expression) between DIO-GAN vehicle and lean control groups. Dotted lines indicate discrimination lines. Solid lines were generated by linear regression analysis of fold change expression values of selected genes in Compound 2-High and Combination-High treatment groups. Selected genes involved in energy and lipid metabolism. Squalene epoxidase (Sqle), 7-dehydrocholesterol (Dhcr7), hydroxymethylgluteraryl-CoA synthase (Hmgcs1), and stearoyl-CoA desaturase (Scd1).
[0037] [Figure 61]Expression of selected genes involved in energy and lipid metabolism is shown. Hepatic expression of genes involved in energy and lipid metabolism. Liver samples were processed for transcriptomics analysis by RNAseq at termination. Bars represent mean (SD) expression (FPKM) values of selected genes involved in energy and lipid metabolism as indicated: Squalene epoxidase (Sqle, A), 7-dehydrocholesterol (Dhcr7, B), hydroxymethylgluteraryl-CoA synthase (Hmgcs1, C), and stearoyl-CoA desaturase (Scd1, D). Lean: white (leftmost bar), DIO-GAN vehicle control: gray (second from left), Compound 3: blue (third from left), Compound 2-Low: light orange (fourth from left), Compound 2-Medium: orange (fifth from left), Compound 2-High: dark orange (fourth from right), Combination-Low: light purple (third from right), Combination-Medium: purple (second from right), Combination-High: dark purple (rightmost bar). Statistical comparisons of individual treatment groups are shown compared to the DIO-GAN vehicle control. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. The combination treatment groups were further compared to Compound 3 (+p<0.05, ++p<0.01, +++p<0.0001, ++++p<0.00001) or their respective Compound 2 monotherapy groups (i.e., Compound 2-low vs. Combination-low) (#p<0.05, ##p<0.01, ###p<0.0001, ####p<0.00001). [Figure 62]Expression of genes involved in fibrosis and inflammation is shown. Hepatic expression of genes involved in fibrosis and inflammation. Liver samples were processed for transcriptomics analysis by RNAseq at termination. Bars represent the mean (SD) expression (FPKM) values of selected genes involved in fibrosis and inflammation: Collagen type I alpha 1 (Col1a1), Actin alpha 2 smooth actin (Acta2), Galectin 3 (Lgals3), and Melanoma cell adhesion molecule (CD146). Lean: white (leftmost bar), DIO-GAN vehicle control: grey (second from left), Compound 3: blue (third from left), Compound 2-low: light orange (fourth from left), Compound 2-medium: orange (fifth from left), Compound 2-high: dark orange (fourth from right), Combination-low: light purple (third from right), Combination-medium: purple (second from right), Combination-high: dark purple (rightmost bar). Statistical comparisons of individual treatment groups are shown relative to DIO-GAN vehicle control. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0038] definition As used herein, the following definitions shall apply unless otherwise indicated. Furthermore, if any term or symbol used herein is not defined as set forth below, it shall have its ordinary meaning in the art.
[0039] "Comprising" is intended to mean that the compositions and methods include the recited elements, but do not exclude other elements. "Consisting essentially of," when used to define compositions and methods, is intended to mean excluding other elements of any essential importance to the combination. For example, a composition consisting essentially of elements as defined herein does not exclude other elements that do not materially affect the basic and novel property(ies) of the claimed invention. "Consisting of" is intended to mean, for example, excluding trace amounts or more of other recited components and substantial method steps. Embodiments defined by each of these conjunctions are within the scope of the invention.
[0040] "Combination therapy" or "combination treatment" refers to the use of two or more drugs or agents in treatment, for example, the use of a compound of formula (I) or (II) as used herein with another agent useful for treating liver disorders such as NAFLD, NASH, and their respective symptoms and signs, which is combination therapy. Administration in "combination" refers to the administration of two agents (e.g., a compound of formula (I) or (II) as used herein and another agent) in any manner that produces both pharmacological effects in the patient at the same time. Thus, administration in combination does not require that a single pharmaceutical composition, the same dosage form, or even the same administration route be used to administer both agents, or that the two agents be administered at exactly the same time. Both agents can also be formulated into a single pharmaceutically acceptable composition. A non-limiting example of such a single composition is an oral composition or oral dosage form. For example, without limitation, it is contemplated that a compound of formula (I) or (II) can be administered in combination therapy with another agent according to the present invention.
[0041] The term "excipient" as used herein means an inert or inactive substance that may be used in the manufacture of a drug or pharmaceutical, such as a tablet, containing a compound of the invention as an active ingredient. A variety of substances may be encompassed by the term excipient, including, but not limited to, any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, solution for parenteral administration, material for chewable tablets, sweetener or flavoring agent, suspending / gelling agent, or wet granulation agent. Binders include, for example, carbomer, povidone, xanthan gum, etc.; coatings include, for example, cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, etc.; compression / encapsulation aids include, for example, calcium carbonate, dextrose, fructose dc (dc = "directly compressible"), honey dc, lactose (anhydrous or monohydrate, optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.; disintegrants include, for example, croscarmellose sodium, gellan gum, sodium starch glycolate, etc.; and creams or lotions. Examples of suitable additives include maltodextrin, carrageenan, etc.; lubricants include magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; chewable tablet materials include dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.; suspending / gelling agents include carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include aspartame, fructose dc, sorbitol, sucrose dc, etc.; and wet granulating agents include calcium carbonate, maltodextrin, microcrystalline cellulose, etc.
[0042] "Patient" refers to a mammal, including humans and non-human mammals. Examples of patients include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows, and humans. In some embodiments, a patient refers to a human.
[0043] "Pharmaceutically acceptable" preferably refers to safe and non-toxic for in vivo, and more preferably for human administration.
[0044] "Pharmaceutically acceptable salt" refers to a salt that is pharma-ceutically acceptable. The compounds described herein may be administered as a pharma-ceutically acceptable salt.
[0045] "Salt" refers to an ionic compound formed between an acid and a base. When the compounds provided herein contain an acidic functional group, such salts include, but are not limited to, alkali metal salts, alkaline earth metal salts, and ammonium salts. As used herein, ammonium salts include salts containing protonated nitrogen bases and alkylated nitrogen bases. Exemplary and non-limiting cations useful in pharma- ceutically acceptable salts include Na, K, Rb, Cs, NH 4 , Ca, Ba, imidazolium, and ammonium cations based on naturally occurring amino acids. When the compounds utilized herein contain a basic functional group, such salts include, but are not limited to, salts with organic acids such as carboxylic acids and sulfonic acids, and mineral acids such as hydrogen halides, sulfuric acids, phosphoric acids, and the like. Exemplary and non-limiting anions useful in pharma-ceutically acceptable salts include oxalate, fumarate, maleate, acetate, propionate, succinate, tartrate, chloride, sulfate, bisulfate, monobasic, dibasic, and tribasic phosphates, mesylate, tosylate, and the like.
[0046] A "therapeutically effective amount" or dose of a compound or composition refers to that amount of the compound or composition that results in a reduction or inhibition of symptoms or a prolongation of survival in a patient. The result may require multiple doses of the compound or composition.
[0047] "Treatment" or "treating" refers to an approach to obtain beneficial or desired results, including clinical results. For purposes of the present invention, beneficial or desired results include, but are not limited to, one or more of the following: reducing one or more symptoms caused by a disease or disorder, reducing the extent of a disease or disorder, stabilizing a disease or disorder (e.g., preventing or delaying the worsening of a disease or disorder), delaying the onset or recurrence of a disease or disorder, delaying or slowing the progression of a disease or disorder, improving the condition of a disease or disorder, providing remission (partial or complete) of a disease or disorder, reducing the dose of one or more other drugs required to treat a disease or disorder, enhancing the effect of another drug used to treat a disease or disorder, slowing the progression of a disease or disorder, improving the quality of life, and / or prolonging the survival of a patient. "Treatment" also encompasses a reduction in the pathological consequences of a disease or disorder. The methods of the present invention contemplate any one or more of these aspects of treatment.
[0048] As used herein, "delaying" the onset of a disease means to prolong, prevent, slow, retard, stabilize, and / or postpone the onset of the disease, and / or to slow the progression of the disease once it has developed, or to change the underlying disease process and / or course. This delay can be of various lengths of time, depending on the disease being treated and / or the individual's medical history. As will be apparent to one of skill in the art, a sufficient or significant delay may actually encompass prevention, in that the individual does not develop clinical symptoms associated with the disease. A method of "delaying" the onset of a disease is one that reduces the probability of disease onset in a given time frame and / or reduces the extent of disease in a given time frame, compared to not using the method, and includes stabilizing one or more symptoms resulting from the disease.
[0049] An individual "at risk" of developing a disease may or may not have detectable disease, and may or may not exhibit detectable disease prior to the treatment methods described herein. "At risk" indicates that an individual has one or more so-called risk factors, which are measurable parameters that correlate with the development of a disease. Individuals who have one or more of these risk factors are more likely to develop the disease than individuals who do not have these risk factor(s). These risk factors include, but are not limited to, age, sex, race, diet, past medical history, presence of precursor diseases, and genetic (i.e., hereditary) considerations. The compounds may, in some embodiments, be administered to subjects (including humans) who are at risk for or have a family history of a disease or condition.
[0050] "Stereoisomer(s)" refers to compounds that differ in the stereogenicity of their constituent atoms, such as, but not limited to, in relation to the chirality of one or more stereocenters or the cis or trans configuration of carbon-carbon or carbon-nitrogen double bonds. Stereoisomers include enantiomers and diastereomers.
[0051] "Alkyl" refers to monovalent saturated aliphatic hydrocarbyl groups having 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms, and more preferably 1 to 6 carbon atoms. This term includes, by way of example, straight-chain and branched-chain hydrocarbyl groups, such as methyl (CH 3 -), ethyl (CH 3 CH 2 -), n-propyl (CH 3 CH 2 CH 2 -), isopropyl ((CH 3 ) 2 CH-), n-Butyl (CH 3 CH 2 CH 2 CH 2 -), isobutyl ((CH 3 ) 2 CHCH 2 -), sec-butyl ((CH 3 )(CH 3 CH 2 )CH-), t-butyl ((CH 3 ) 3 C-), n-pentyl (CH 3 CH 2 CH 2 CH 2 CH 2 -), and neopentyl ((CH 3 ) 3 CCH 2 -) and others. C x Alkyl refers to an alkyl group having x carbon atoms.
[0052] "Alkylene" refers to a divalent saturated aliphatic hydrocarbyl group having 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms, and more preferably 1 to 6 carbon atoms. This term includes, by way of example, straight and branched chain hydrocarbyl groups, such as methylene (-CH 2 -), ethylene (-CH 2 CH 2 - or -CH(Me)-), propylene (-CH 2 CH 2 CH 2 - or -CH(Me)CH 2 -, -CH(Et)-, and the like.
[0053] "Alkenyl" refers to straight or branched chain monovalent hydrocarbyl groups having from 2 to 6 carbon atoms, preferably from 2 to 4 carbon atoms, and having at least one, preferably one or two sites of vinyl (>C=C<) unsaturation. Such groups are exemplified, for example, by vinyl, allyl, and but-3-en-1-yl. Included within this term are cis and trans isomers or mixtures of these isomers. x Alkenyl refers to an alkenyl group having x carbon atoms.
[0054] "Alkynyl" refers to a straight or branched chain monovalent hydrocarbyl group having from 2 to 6 carbon atoms, preferably from 2 to 3 carbon atoms, and having at least one, preferably 1 to 2 sites of acetylenic (-C≡C-) unsaturation. Examples of such alkynyl groups are acetylenyl (-C≡CH), and propargyl (-CH 2 C≡CH). x Alkynyl refers to an alkynyl group having x carbon atoms.
[0055] "Alkoxy" refers to the group -O-alkyl, where alkyl is defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.
[0056] "Aryl" refers to a monovalent aromatic carbocyclic group of 6 to 14 carbon atoms having a single ring (e.g., phenyl (Ph)) or multiple condensed rings (e.g., naphthyl or anthryl) which may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)-one-7-yl, etc.), provided that the point of attachment is at an aromatic carbon atom. Preferred aryl groups include phenyl and naphthyl.
[0057] "Cyano" refers to the group -C≡N.
[0058] "Cycloalkyl" refers to a saturated or unsaturated, but non-aromatic, cyclic alkyl group of 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, and more preferably 3 to 6 carbon atoms, having single or multiple cyclic rings, including fused, bridged, and spiro ring systems. x Cycloalkyl refers to a cycloalkyl group having x ring carbon atoms. Examples of suitable cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl. One or more of the rings can be aryl, heteroaryl, or heterocyclic, provided that the point of attachment is through a non-aromatic, non-heterocyclic, saturated carbocyclic ring. "Substituted cycloalkyl" includes oxo, thione, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio, substituted arylthio, carboxyl ... ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio, substituted cycloalkylthio, guanidino, substituted guanidino, halo, hydroxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, heterocyclylthio, substituted heterocyclylthio, nitro, SO 3 H, substituted sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, and substituted alkylthio, wherein the substituents are defined herein.
[0059] "Halo" or "halogen" refers to fluoro, chloro, bromo and iodo, preferably fluoro or chloro.
[0060] "Hydroxy" or "hydroxyl" refers to the group --OH.
[0061] "Heteroaryl" refers to an aromatic group of 1-10 carbon atoms in the ring and 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. Such heteroaryl groups can have a single ring (e.g., pyridinyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl), which may or may not be aromatic and / or contain heteroatoms, provided that the point of attachment is through an atom of the aromatic heteroaryl group. In one embodiment, the nitrogen and / or sulfur ring atom(s) of the heteroaryl group are optionally oxidized to provide an N-oxide (N→O), sulfinyl, or sulfonyl moiety. Preferred heteroaryls include 5- or 6-membered heteroaryls, such as pyridinyl, pyrrolyl, thiophenyl, and furanyl. Other preferred heteroaryls include 9- or 10-membered heteroaryls, such as indolyl, quinolinyl, quinolonyl, isoquinolinyl, and isoquinolonyl.
[0062] "Heterocycle" or "heterocyclic" or "heterocycloalkyl" or "heterocyclyl" refers to a saturated or partially saturated, but not aromatic, group having 1 to 10 ring carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms, and 1 to 4 ring heteroatoms, preferably 1 to 3 heteroatoms, more preferably 1 to 2 heteroatoms, selected from the group consisting of nitrogen, sulfur, or oxygen. xHeterocycloalkyl refers to a heterocycloalkyl group having x ring atoms, including a ring heteroatom. Heterocycles encompass single or multiple fused rings, which include fused, bridged, and spiro ring systems. In fused ring systems, one or more of the rings can be cycloalkyl, aryl, or heteroaryl, provided that the point of attachment is through a non-aromatic ring. In one embodiment, the nitrogen and / or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide N-oxide, sulfinyl, sulfonyl moieties.
[0063] Examples of heterocyclyl and heteroaryl include azetidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazyl, pyrimidyl, pyridazyl, indolizyl, isoindolyl, indolyl, dihydroindolyl, indazolyl, purinyl, quinolidinyl, isoquinolinyl, quinolinyl, phthalazinyl, naphthylpyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, isothiazolyl, phenazinyl, isoxazolyl, and the like. These include, but are not limited to, phenyl, phenoxazinyl, phenothiazinyl, imidazolidinyl, imidazolinyl, piperidinyl, piperazinyl, indolinyl, phthalimidyl, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrobenzo[b]thiophenyl, thiazolyl, thiazolidinyl, thiophenyl, benzo[b]thiophenyl, morpholinyl, thiomorpholinyl (also referred to as thiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidinyl, and tetrahydrofuranyl.
[0064] "Oxo" refers to the atom (=O) or (O).
[0065] The terms "optional" or "optionally," as used throughout this specification, are meant to indicate that the subsequently described event or circumstance may, but need not, occur, and that the description includes situations in which the event or circumstance occurs and situations in which it does not occur. For example, "a nitrogen atom is optionally oxidized to provide an N-oxide (N→O) moiety" means that the nitrogen atom may, but need not, be oxidized, and that the description includes situations in which the nitrogen atom is not oxidized and situations in which the nitrogen atom is oxidized.
[0066] Dosage amounts of the compounds as described herein are suitably determined based on the free acid or free base of the compound.
[0067] SSAO inhibitors Suitable SSAO inhibitors that may be used according to the methods described herein include, but are not limited to, PXS-4728A (BI-1467335) and compounds of formula (I) or pharma- ceutically acceptable salts. Compounds of formula (I), including Compound 1, are disclosed in US2018 / 0297987, the entire contents of which are incorporated by reference, specifically with respect to compounds of formula (I) or pharma- ceutically acceptable salts or enantiomers thereof, as well as methods of making and using the foregoing.
[0068] In some embodiments, the SSAO inhibitor is a compound represented by formula (I): [ka] or a pharma- ceutically acceptable salt thereof, wherein n is 1 or 2; R1 is H or -CH 3 It is.
[0069] [ka] The bond to the fluorine, depicted as: indicates that the fluorine atom and the methoxypyrimidine group can be either Z (zusammen, together) or E (entgegen, opposite) relative to each other (Brecher, J., et al., "Graphical Representation of Stereochemical Configuration", Pure and Appl. Chem, 2006, 78(10)1897, at 1959). The structure depicted in formula (II) includes compounds having a Z stereochemical configuration, an E stereochemical configuration, or a mixture of compounds of Z or E stereochemical configuration. Preferred compounds of the invention have an E stereochemical configuration.
[0070] In one form, the compound of formula (I) is presented as a free base. In another form, the compound of formula (I) is presented as an acid addition salt, such as a mono- or di-HCl addition salt(s) or a sulfonate salt, preferably a 4-methylbenzenesulfonate salt (tosylate salt).
[0071] In some embodiments, the SSAO inhibitor is represented by formula (Ia): [ka] or a pharma- ceutically acceptable salt thereof, wherein n is 1 or 2; R1 is H or -CH 3 It is.
[0072] In some embodiments, the SSAO inhibitor is [ka] or a pharma- ceutically acceptable salt thereof, n is 1 or 2; R1 is H or -CH 3 It is.
[0073] In some embodiments, the SSAO inhibitor is a compound of formula (I), (Ia) or (Ib), and n is 2.
[0074] In some embodiments, the SSAO inhibitor is a compound of formula (I), (Ia) or (Ib), wherein R is CH 3 It is.
[0075] In some embodiments, the SSAO inhibitor has Formula 1: [ka] or a pharma- ceutically acceptable salt thereof, such as, for example, the dihydrochloride or 4-methylbenzenesulfonate salt. "Compound 1" refers to a compound of formula 1.
[0076] THR-β agonists Suitable THR-β agonists that may be used in accordance with the methods described herein include, but are not limited to, resmetirom (MGL-3196), VK2809 (by Viking Therapeutics), sobetirom, eprotirom, ALG-055009 (by Aligo), CNPT-101101 (by FronThera Pharmaceuticals), CNPT-101207 (by FronThera Pharmaceuticals), ASC41 (Ascletis), and the compound of formula (II) or a pharma- ceutical acceptable salt.
[0077] Compounds of formula (II) are disclosed in U.S. Application Publication No. 20200190064, the entire contents of which are incorporated by reference, specifically with respect to compounds of formula (II), such as Compound 2, or pharma- ceutically acceptable salts or enantiomers thereof, as well as methods of making and using the foregoing.
[0078] In some embodiments, the THR-β agonist is represented by formula (II): [ka] A compound of the formula R 1 is hydrogen, cyano, substituted or unsubstituted C1~6 Alkyl, and substituted or unsubstituted C 3~6 cycloalkyl, the substituents being halogen atoms, hydroxy, and C 1~6 alkoxy; R 2 and R 3 is a halogen atom and a substituted or unsubstituted C 1~6 alkyl, each independently selected from the group consisting of halogen, hydroxy, and C 1~6 alkoxy; Ring A is a substituted or unsubstituted saturated or unsaturated C 5~10 Aliphatic ring, or substituted or unsubstituted C 5~10 Aromatic ring with a substituent of hydrogen, halogen atom, hydroxyl, -OCF 3 , -NH 2 , -NHC 1~4 Alkyl, -N(C 1~4 Alkyl) 2 , -CONH 2 , -CONHC 1~4 Alkyl, -CON(C 1~4 Alkyl) 2 , -NHCOC 1~4 Alkyl, C 1~6 Alkyl, C 1~6 Alkoxy and C 3~6 one or more substances selected from the group consisting of cycloalkyl, where when two substituents are contained, the two substituents may form a ring structure together with the carbons to which they are attached; the halogen atoms are selected from the group consisting of F, Cl and Br; Or a pharma- ceutically acceptable salt thereof.
[0079] In some embodiments, the THR-β agonist is represented by formula (IIa): [ka] A compound of the formula R 1 ~R 3 is defined as detailed herein for formula (II), R4 However, hydrogen, halogen atoms, hydroxyl, -OCF 3 , -NH 2 , -NHC 1~4 Alkyl, -N(C 1~4 Alkyl) 2 , -CONH 2 , -CONHC 1~4 Alkyl, -CON(C 1~4 Alkyl) 2 , -NHCOC 1~4 Alkyl, C 1~6 Alkyl, C 1~6 Alkoxy and C 3~6 cycloalkyl; m is an integer ranging from 1 to 4; the halogen atoms are selected from the group consisting of F, Cl and Br; or a pharma- ceutically acceptable salt thereof.
[0080] In some embodiments, R 4 is hydrogen, halogen atom, hydroxy, -OCF 3 , C 1~6 Alkyl, C 1~6 Alkoxy and C 3~6 cycloalkyl, and m is an integer ranging from 1 to 3.
[0081] In some embodiments, R 1 is hydrogen, cyano, and substituted or unsubstituted C 1~6 alkyl, and the substituents are halogen atoms, hydroxy, and C 1~6 The alkoxy group is selected from the group consisting of halogen atoms, and the halogen atoms are selected from the group consisting of F, Cl and Br.
[0082] In some embodiments, the THR-β agonist has Formula 2: [ka] or a pharma- ceutically acceptable salt thereof, such as, for example, a potassium or sodium salt. "Compound 2" refers to a compound of formula 2.
[0083] FXR agonists Suitable FXR agonists that may be used according to the methods described herein include, but are not limited to, obeticholic acid, cilofexor, tropifexor, EYP001 (bonafexor, proposed INN), MET409 (Metacrine), EDP-305 (by Enanta) and compounds of formula (I) or pharma- ceutically acceptable salts. Compounds of formula (III), including compound 3, are disclosed in US2010 / 0152166, the entire contents of which are incorporated by reference, specifically with respect to compounds of formula (I) or pharma- ceutically acceptable salts or enantiomers thereof, as well as methods of making and using the foregoing.
[0084] In some embodiments, the FXR agonist is represented by formula (III): [ka] A compound of the formula q is 1 or 2; R 1 is chloro, fluoro, or trifluoromethoxy; R 2 is hydrogen, chloro, fluoro, or trifluoromethoxy; R 3a is trifluoromethyl, cyclopropyl, or isopropyl; X is CH or N, with the proviso that when X is CH, q is 1; Ar 1 is indolyl, benzothienyl, naphthyl, phenyl, benzisothiazolyl, indazolyl, or pyridinyl, each of which is optionally substituted with methyl or phenyl; or a pharma- ceutically acceptable salt thereof.
[0085] In some embodiments, the FXR agonist is a compound of formula (III), wherein R 1 is chloro or trifluoromethoxy, R2 is hydrogen or chloro.
[0086] In some embodiments, the FXR agonist is a compound of formula (III), wherein R 3a is cyclopropyl or isopropyl.
[0087] In some embodiments, the FXR agonist is a compound of formula (III), wherein Ar 1 is 5-benzothienyl, 6-benzothienyl, 5-indolyl, 6-indolyl, or 4-phenyl, each of which is optionally substituted with methyl.
[0088] In some embodiments, the FXR agonist is a compound of formula (III), wherein q is 1 and X is N.
[0089] In some embodiments, the FXR agonist has formula 3: [ka] or a pharma- ceutically acceptable salt thereof. "Compound 3" refers to the compound of formula 3.
[0090] Pharmaceutically acceptable compositions and formulations Any pharma- ceutically acceptable composition or simply "pharmaceutical composition" of the compounds detailed herein is encompassed by the present invention. Thus, the present invention includes a pharmaceutical composition comprising an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof), a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and a pharma- ceutically acceptable carrier or excipient. In some embodiments, the pharma- ceutical acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid. The pharmaceutical composition according to the present invention may be in a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or in a form suitable for administration by inhalation.
[0091] The compounds as detailed herein may, in one aspect, be in purified form, and compositions comprising the compounds in purified form are detailed herein. Compositions comprising the compounds as detailed herein or salts thereof are provided, such as compositions of substantially pure compounds. In some embodiments, compositions containing the compounds as detailed herein or salts thereof are in substantially pure form. In one variation, "substantially pure" contemplates a composition containing 35% or less impurities, impurities referring to compounds other than the compound contained in the majority of the composition or salts thereof. For example, a composition of a substantially pure compound contemplates a composition containing 35% or less impurities, impurities referring to compounds other than the compound or salts thereof. In one variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 25% or less impurities. In another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 20% or less impurities. In yet another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 10% or less impurities. In a further variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 5% or less impurities. In another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 3% or less of impurities. In yet another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 1% or less of impurities. In a further variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 0.5% or less of impurities. In yet another variation, a composition of a substantially pure compound means that the composition contains 15% or less of impurities, or preferably 10% or less of impurities, or more preferably 5% or less of impurities, or even more preferably 3% or less of impurities, and most preferably 1% or less of impurities, which may be compounds of different stereochemical forms.
[0092] In one variation, the compounds herein are synthetic compounds prepared for administration to an individual, such as a human. In another variation, compositions containing the compounds in substantially pure form are provided. In another variation, the invention encompasses pharmaceutical compositions comprising the compounds detailed herein and a pharma- ceutically acceptable carrier or excipient. In another variation, methods of administering the compounds are provided. The purified forms, pharmaceutical compositions, and methods of administering the compounds are suitable for any of the compounds detailed herein or forms thereof.
[0093] The compounds may be formulated for any available delivery route, including oral, mucosal (e.g., nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery forms. The compounds may be formulated with suitable carriers to provide a delivery form, including, but not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, poultices, pastes, powders, bandages, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
[0094] The compounds described herein can be used to prepare formulations such as pharmaceutical preparations by combining the compound as an active ingredient with a pharma- ceutically acceptable carrier, such as those described above. Depending on the therapeutic form of the system (e.g., transdermal patch vs. oral tablet), the carrier can be in various forms. In addition, pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants. Preparations containing the compounds can also contain other substances that have beneficial therapeutic properties. Pharmaceutical preparations can be prepared by known pharmaceutical methods. Suitable formulations can be found, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams&Wilkins, 21st ed.(2005), which is incorporated herein by reference.
[0095] The compounds as described herein may be administered to an individual (e.g., a human) in the form of a generally acceptable oral composition, such as tablets, coated tablets, and hard or soft shell gel capsules, emulsions or suspensions. Examples of carriers that may be used to prepare such compositions include lactose, corn starch or its derivatives, talc, stearates or salts thereof, etc. Acceptable carriers for gel capsules with soft shells include, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols, etc. In addition, pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants.
[0096] Described herein are compositions that contain two compounds (SSAO inhibitor and THR-β agonist) or three compounds (SSAO inhibitor, THR-β agonist, and FXR agonist) utilized herein. Any of the compounds described herein can be formulated into a tablet of any dosage form described herein.
[0097] The present disclosure further encompasses kits (e.g., pharmaceutical packages). The kits provided may include a pharmaceutical composition or compound described herein and a container (e.g., a pharmaceutical bottle, an ampoule, a bottle, a syringe, and / or a subpackage, or other suitable container). In some embodiments, the kit includes a container containing an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof). In some such embodiments, the container further includes an FXR agonist (such as a compound of formula (III) or a pharma- ceutically acceptable salt thereof). In other embodiments, the kit includes a first container containing an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a second container containing a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof). In some such embodiments, the kit further includes a third container containing an FXR agonist (such as a compound of formula (III) or a pharma- ceutically acceptable salt thereof).
[0098] In some embodiments, the composition comprises an SSAO inhibitor and a THR-β agonist as described herein. In some embodiments, such a composition comprises a compound of formula (I), or a pharma- ceutically acceptable salt thereof, and a compound of formula (II), or a pharma- ceutically acceptable salt thereof. In some embodiments, a dosage form is provided herein comprising a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt thereof, and a therapeutically effective amount of a compound of formula (II), or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula (I), or a pharma- ceutically acceptable salt thereof, is compound 1, or a pharma- ceutically acceptable salt thereof, as described herein, and the compound of formula (II), or a pharma- ceutically acceptable salt thereof, is compound 2, or a pharma- ceutically acceptable salt thereof, as described herein. In some of the foregoing embodiments, the composition further comprises an FXR agonist as described herein. In some such embodiments, the FXR agonist is a compound of formula (III), or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula (III) is compound 3, or a pharma- ceutically acceptable salt thereof, as described herein.
[0099] Method and use The compounds and compositions described herein may be used in some aspects to treat or prevent liver damage. In some embodiments, a method for treating or preventing liver damage in a patient in need of treatment or prevention of liver damage comprises administering a semicarbazide-sensitive amine oxidase (SSAO) inhibitor and a thyroid hormone receptor beta (THR-β) agonist to the patient. In some embodiments, the method further comprises administering an FXR agonist to the patient, including but not limited to compound 3. In some embodiments, the SSAO inhibitor is a compound of formula (I), or a pharma- ceutically acceptable salt thereof, and the THR-β agonist is a compound of formula (II), or a pharma- ceutically acceptable salt thereof. In one embodiment, the compound of formula (I), or a pharma- ceutically acceptable salt thereof, is compound 1, and the compound of formula (II), or a pharma- ceutically acceptable salt thereof, is compound 2, as described herein. Without wishing to be bound by theory, it is believed that the combination of an SSAO inhibitor and a THR-β agonist according to the methods described herein may provide an effective treatment when compared to monotherapy, and therefore reduce the dose-dependent adverse effects that may be associated with monotherapy treatment.
[0100] Liver disorders include, but are not limited to, liver inflammation, fibrosis, and steatohepatitis. In some embodiments, the liver disorder is selected from liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). In certain embodiments, the liver disorder is selected from liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, NAFLD, and NASH. In one embodiment, the liver disorder is NASH. In another embodiment, the liver disorder is liver inflammation. In another embodiment, the liver disorder is liver fibrosis. In another embodiment, the liver disorder is alcoholic fibrosis. In another embodiment, the liver disorder is steatosis. In another embodiment, the liver disorder is alcoholic steatosis. In another embodiment, the liver disorder is NAFLD. In one embodiment, the therapeutic method provided herein prevents or slows the progression of NAFLD to NASH. In one embodiment, the therapeutic method provided herein prevents or slows the progression of NASH. NASH can progress to, for example, one or more of cirrhosis, liver cancer, etc. In some embodiments, the liver disorder is NASH. In some embodiments, the patient has undergone liver biopsy. In some embodiments, the method further comprises obtaining the results of liver biopsy.
[0101] In some embodiments, a method of treating liver damage in a patient in need of treatment, wherein the liver damage is selected from the group consisting of liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
[0102] Provided herein is a method for treating or preventing liver damage in a patient (e.g., a human patient) in need of such treatment or prevention with an SSAO inhibitor and a THR-β agonist, the method comprising administering a therapeutically effective amount of an SSAO inhibitor and a therapeutically effective amount of a THR-β agonist, wherein the liver damage is selected from liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). In some embodiments, the method further comprises an FXR agonist, including but not limited to compound 3. In some embodiments, the SSAO inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof, and the THR-β agonist is a compound of formula (II) or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of formula (I), or a pharma- ceutically acceptable salt thereof, is compound 1, and the compound of formula (II), or a pharma- ceutically acceptable salt thereof, is compound 2, as described herein.
[0103] Also provided herein is a method of preventing or slowing the progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) in a patient (e.g., a human patient) in need thereof, the method comprising administering an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof). In some embodiments, the method further comprises administering an FXR agonist, including but not limited to compound 3. In some embodiments, the method comprises administering a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt thereof, and a therapeutically effective amount of a compound of formula (II), or a pharma- ceutically acceptable salt thereof, and optionally a therapeutically effective amount of a compound of formula (III), or a pharma- ceutically acceptable salt thereof. Also provided herein is a method of preventing or slowing the progression of NASH in a patient (e.g., a human patient) in need thereof, the method comprising administering an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof). In some embodiments, the method further comprises administering an FXR agonist, including but not limited to compound 3. In some embodiments, the method comprises administering a therapeutically effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt thereof, and a therapeutically effective amount of a compound of formula (II), or a pharma- ceutically acceptable salt thereof, and optionally a therapeutically effective amount of a compound of formula (III), or a pharma- ceutically acceptable salt thereof.
[0104] In the patient, alkaline phosphatase, gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) levels may be elevated. In some embodiments, a method of reducing liver damage is provided herein, the method comprising administering a SSAO inhibitor (such as a compound of formula (I) or a pharma-ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma-ceutically acceptable salt thereof), wherein GGT, ALT and / or AST levels are elevated prior to treatment with the SSAO inhibitor. In some embodiments, the SSAO inhibitor is a compound of formula (I) or a pharma-ceutically acceptable salt thereof.
[0105] In some embodiments, provided herein is a method of treating liver damage in a patient in need thereof with an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), wherein the SSAO inhibitor selectively inhibits SSAO. In some embodiments, the SSAO inhibitor is a compound of formula (I) or a pharma- ceutically acceptable salt thereof. Thus, in some embodiments, MAO-A (monoamine oxidase A) is not inhibited. In some embodiments, MAO-B (monoamine oxidase B) is not inhibited. In some embodiments, MAO-A and MAO-B are not inhibited.
[0106] In some embodiments, the patient is a human. Obesity is highly correlated with NAFLD and NASH, but lean people can also be affected by NAFLD and NASH. Thus, in some embodiments, the patient is obese. In some embodiments, the patient is not obese. Obesity can also be correlated with or cause other diseases, such as diabetes or cardiovascular disorders. Thus, in some embodiments, the patient also has diabetes and / or cardiovascular disorders. Without being bound by theory, it is believed that comorbidities such as obesity, diabetes, and cardiovascular disorders can make NAFLD and NASH more difficult to treat. Conversely, the only currently recognized way to address NAFLD and NASH is weight loss, which may have little or no effect on lean patients.
[0107] Although the risk of NAFLD and NASH increases with age, children can also suffer from NAFLD and NASH, with literature reports of children as young as 2 years old (Schwimmer, et al., Pediatrics, 2006, 118:1388-1393). In some embodiments, the patient is 2-17 years old, such as 2-10, 2-6, 2-4, 4-15, 4-8, 6-15, 6-10, 8-17, 8-15, 8-12, 10-17, or 13-17 years old. In some embodiments, the patient is 18-64 years old, such as 18-55, 18-40, 18-30, 18-26, 18-21, 21-64, 21-55, 21-40, 21-30, 21-26, 26-64, 26-55, 26-40, 26-30, 30-64, 30-55, 30-40, 40-64, 40-55, or 55-64 years old. In some embodiments, the patient is 65 years old or older, such as 70 years old or older, 80 years old or older, or 90 years old or older.
[0108] NAFLD and NASH are common causes of liver transplantation, but patients who have already undergone one liver transplant often develop NAFLD and / or NASH again. Thus, in some embodiments, the patient has undergone a liver transplant.
[0109] In some embodiments, treatment with the methods provided herein results in a reduction in NAFLD activity (NAS) score in a patient. For example, in some embodiments, steatosis, inflammation, and / or ballooning are reduced upon treatment. In some embodiments, the treatment methods provided herein reduce liver fibrosis. In some embodiments, the methods reduce serum triglycerides. In some embodiments, the methods reduce liver triglycerides.
[0110] In some embodiments, the patient is at risk of developing an adverse effect prior to administration according to the methods provided herein, hi some embodiments, the adverse effect is an adverse effect affecting the kidneys, lungs, heart, and / or skin.
[0111] In some embodiments, the patient has previously undergone one or more therapies, hi some embodiments, the liver damage progressed during therapy.
[0112] In some embodiments, the methods do not include administering antihistamines, immunosuppressants, steroids (such as corticosteroids), rifampicin, opioid antagonists, or selective serotonin reuptake inhibitors (SSRIs).
[0113] In some embodiments, the SSAO inhibitor and the THR-β agonist, and optionally the FXR agonist, are administered simultaneously. In some such embodiments, the SSAO inhibitor and the THR-β agonist, and optionally the FXR agonist, can be provided in a single pharmaceutical composition. In other embodiments, the SSAO inhibitor and the THR-β agonist, and optionally the FXR agonist, are administered sequentially.
[0114] When administered in combination with a THR-β agonist, the SSAO inhibitor and / or the THR-β agonist and / or the optional FXR agonist may be administered at a dose that is typically administered when either agent is administered alone. Alternatively, as a result of observed potential synergistic effects with the combination, the SSAO and / or the THR-β agonist and / or the optional FXR agonist may be administered at a lower dose than the dose at which each agent is administered alone.
[0115] In embodiments where the SSAO inhibitor is Compound 1 or a pharma- ceutically acceptable salt thereof, the therapeutic dose of the compound for a human patient is typically orally administered from about 4 mg to about 40 mg per day. In certain embodiments, when administered in combination with a THR-β agonist, and optionally further in combination with an FXR agonist, the compound of formula (I) or a pharma- ceutically acceptable salt thereof may be administered in an oral dose of about 4 mg to about 20 mg (e.g., 4 mg, 5 mg, 6 mg, 8 mg, 10 mg, 15 mg, or 20 mg), or may be administered in a lower dose. For example, when administered in combination with a THR-β agonist, and optionally further in combination with an FXR agonist, the compound of formula (I) or a pharma- ceutically acceptable salt thereof may be orally administered at a dose of about 1 mg to about 40 mg per day, about 1 mg to about 20 mg per day, about 1 mg to about 3.9 mg per day, about 1 mg to about 3 mg per day, about 1.5 mg to about 3.5 mg per day, about 2 mg to about 3 mg per day, or 1, 1.5, 2, 2.5, 3, 3.5, 3.6, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg per day.
[0116] In embodiments where the THR-β agonist is compound 2 or a pharma- ceutically acceptable salt thereof, the therapeutic dose of each compound for a human patient is typically orally administered at about 0.5 mg to about 90 mg per day, about 1 mg to about 90 mg per day, about 3 mg to about 90 mg per day, about 0.5 mg to about 30 mg per day, about 1 mg to about 30 mg per day, or about 3 mg to about 30 mg per day. In certain embodiments, when administered in combination with an SSAO inhibitor, and optionally further in combination with an FXR agonist, the compound of formula (II) or a pharma- ceutically acceptable salt thereof may be administered at an oral dose of about 0.5 mg to about 90 mg (e.g., 0.5 mg, 1 mg, 3 mg, 5 mg, 6 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, or 90 mg), or at a lower dose. For example, when administered in combination with an SSAO inhibitor, and optionally further in combination with an FXR agonist, the compound of formula (II) or a pharma- ceutically acceptable salt thereof may be orally administered at a dose of about 0.1 mg to about 90 mg per day, about 0.1 mg to about 30 mg per day, about 0.1 mg to about 25 mg per day, about 0.1 mg to about 20 mg per day, about 0.1 mg to about 15 mg per day, about 0.1 mg to about 10 mg per day, about 0.1 mg to about 5 mg per day, about 0.1 mg to about 3 mg per day, or about 0.1 mg to about 1 mg per day.
[0117] In embodiments where the FXR agonist is compound 3 or a pharma- ceutically acceptable salt thereof, the therapeutic dose of the compound for a human patient is typically orally administered from about 5 mg to about 75 mg per day, or from about 5 mg to about 25 mg per day, preferably from about 10 mg to about 15 mg per day. In certain embodiments, when administered in combination with an SSAO inhibitor and a THR-β agonist, the compound of formula (III) or a pharma- ceutically acceptable salt thereof may be administered at an oral dose of about 5 mg to about 75 mg, or at a lower dose. For example, when administered in combination with an SSAO inhibitor and a THR-β agonist, the compound of formula (III) or a pharma- ceutically acceptable salt thereof may be orally administered at a dose of about 1 mg to about 75 mg per day, about 5 mg to about 75 mg per day, about 1 mg to about 25 mg per day, about 1 mg to about 15 mg per day, about 1 mg to about 10 mg per day, about 1 mg to about 5 mg per day, or about 5 mg to about 10 mg per day.
[0118] In certain embodiments in which the SSAO inhibitor is a compound of formula (I) (e.g., compound 1) or a pharma- ceutically acceptable salt thereof, and the THR-β agonist is a compound of formula (II) (e.g., compound 2) or a pharma- ceutically acceptable salt thereof, optionally further combined with an FXR agonist, the doses of the individual compounds may be administered as described above. For example, in some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof may be administered at a dose of about 1 mg to about 40 mg per day, and may be combined with compound 2 or a pharma- ceutically acceptable salt thereof administered at a dose of about 0.1 mg to about 90 mg per day, and may be optionally combined with compound 3 or a pharma- ceutically acceptable salt thereof administered at a dose of about 1 mg to about 75 mg per day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof is administered at a dose of about 1 mg to about 20 mg per day, combined with compound 2 or a pharma- ceutically acceptable salt thereof administered at a dose of about 0.1 mg to about 30 mg per day, and optionally combined with compound 3 or a pharma- ceutically acceptable salt thereof administered at a dose of about 1 mg to about 20 mg per day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof is administered at a dose of about 1 mg to about 10 mg per day, combined with compound 2 or a pharma- ceutically acceptable salt thereof administered at a dose of about 0.1 mg to about 10 mg per day, and optionally combined with compound 3 or a pharma- ceutically acceptable salt thereof administered at a dose of about 1 mg to about 15 mg per day. In some embodiments, compound 1, or a pharma- ceutically acceptable salt thereof, is administered at a dose of about 1 mg to about 6 mg per day, combined with compound 2, or a pharma- ceutically acceptable salt thereof, administered at a dose of about 0.1 mg to about 5 mg per day, and optionally combined with compound 3, or a pharma- ceutically acceptable salt thereof, administered at a dose of about 1 mg to about 10 mg per day.
[0119] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered at a dose of about 5 mg to about 15 mg per day, and may be combined with a compound of formula (II) or a pharma- ceutically acceptable salt thereof administered at a dose of about 0.1 mg to about 10 mg per day, about 10 mg to about 20 mg per day, about 10 mg to about 40 mg per day, about 20 mg to about 50 mg per day, or about 50 mg to about 90 mg per day. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt thereof is administered at a dose of about 1 mg to about 5 mg per day, and may be combined with a compound of formula (II) or a pharma- ceutically acceptable salt thereof administered at a dose of about 0.1 mg to about 10 mg per day, about 10 mg to about 20 mg per day, about 10 mg to about 40 mg per day, about 20 mg to about 50 mg per day, or about 50 mg to about 90 mg per day.
[0120] In some embodiments, the amount of the SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and the amount of the THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally the amount of the FXR agonist, administered on day 1 of the treatment period may be equal to or greater than the amount of the compound administered on all subsequent days of the treatment period. In some embodiments, the amount of each compound administered on day 1 of the treatment period may be equal to the amount of the compound administered on all subsequent days of the treatment period.
[0121] The compound of formula (I), or a pharma- ceutically acceptable salt thereof, used according to the methods described herein may be administered to an individual in a dose once a day for a first period, followed by a second period in which administration of the compound is discontinued, and SSAO inhibitory activity may be maintained in both the first and second periods. In some embodiments, the first and second periods are each a one week period. For example, a method of treatment in an individual for 14 days is provided herein, the method includes administering a compound of formula (I), or a pharma- ceutically acceptable salt thereof, to the individual in a dose once a day for the first 7 days, followed by discontinuing administration of the compound for the next 7 days, and SSAO inhibitory activity may be maintained in the individual throughout the entire 14 days. As another example, a method of treatment in an individual for 4 weeks is provided herein, the method includes administering a compound of formula (I), or a pharma- ceutically acceptable salt thereof, to the individual in a dose once a day for the first 2 weeks, followed by discontinuing administration of the compound for the next 2 weeks, and SSAO inhibitory activity may be maintained in the individual throughout the entire 4 weeks. In some embodiments, the daily dose is about 10 mg. It is understood that the dosages and dosing regimens disclosed herein are also applicable to the monotherapy of treating NASH using the compound of formula (I), or a pharma- ceutically acceptable salt thereof.
[0122] In some embodiments, administration of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces adiposity in an individual. Methods for assessing adiposity are known to those skilled in the art and may include histological analysis and evaluation of histological scores. In some embodiments, administration of the combination may reduce adiposity in an individual compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. In some embodiments, administration of the combination may reduce adiposity in an individual equivalent to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. In some embodiments, administration of the combination may provide a synergistic reduction in adiposity in an individual compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. Thus, the methods of treatment detailed herein, in some embodiments, include treating liver disorders such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) in an individual in need thereof, where treatment is understood to include reducing histological markers associated with steatosis.
[0123] In some embodiments, administration of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces inflammation in the liver of an individual. Methods for assessing liver inflammation are known to those skilled in the art and may include histological analysis of lobular inflammation and evaluation of histological scores. In some embodiments, administration of the combination may reduce inflammation in the liver of an individual compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. In some embodiments, administration of the combination may reduce inflammation in the liver of an individual equivalent to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. In some embodiments, administration of the combination may provide a synergistic reduction in inflammation in the liver of an individual compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. Thus, the methods of treatment detailed herein, in some embodiments, include treating liver disorders such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) in an individual in need of such treatment, where treatment is understood to include reducing lobular inflammation or histological markers associated with lobular inflammation.
[0124] In some embodiments, administering a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces liver fibrosis in an individual. Methods for assessing liver fibrosis are known to those skilled in the art and may include histological analysis. In some embodiments, administering a combination may reduce liver fibrosis in an individual compared to administering a SSAO inhibitor or a THR-β agonist in monotherapy. In some embodiments, administering a combination may reduce liver fibrosis in an individual equivalent to administering a SSAO inhibitor or a THR-β agonist in monotherapy. In some embodiments, administering a combination may provide a synergistic reduction in liver fibrosis in an individual compared to administering a SSAO inhibitor or a THR-β agonist in monotherapy. Thus, the methods of treatment detailed herein, in some embodiments, include treating liver disorders such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) in an individual in need thereof, where treatment is understood to include reducing fibrosis or histological markers associated with fibrosis.
[0125] In some embodiments, administration of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces at least one or at least two of hepatic steatosis, inflammation, and fibrosis in an individual. In some embodiments, administration of the combination may reduce at least one or at least two of hepatic steatosis, inflammation, and fibrosis in an individual, when compared to administration of an SSAO inhibitor or a THR-β agonist monotherapy. In some embodiments, administration of the combination may reduce hepatic steatosis, inflammation, and fibrosis in an individual. In some embodiments, administration of the combination may reduce hepatic steatosis, inflammation, and fibrosis in an individual, when compared to administration of an SSAO inhibitor or a THR-β agonist monotherapy. In some embodiments, the administration of the combination may provide a synergistic reduction in at least one or at least two of steatosis, inflammation, and fibrosis in an individual when compared to administration of a SSAO inhibitor or a THR-β agonist monotherapy. In some embodiments, the administration of the combination may provide a synergistic reduction in steatosis, inflammation, and fibrosis in an individual when compared to administration of a SSAO inhibitor or a THR-β agonist monotherapy. Thus, the method of treatment detailed herein, in some embodiments, includes treating a liver disorder, such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), in an individual in need of such treatment, wherein the treatment includes reducing at least one or at least two of steatosis, lobular inflammation, fibrosis, or any of the histological markers described above.
[0126] In some embodiments, administration of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces serum triglycerides in an individual. In some embodiments, administration of the combination may reduce serum triglycerides in an individual as compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. In some embodiments, administration of the combination may reduce serum triglycerides in an individual equivalent to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. Thus, the methods of treatment detailed herein, in some embodiments, include treating liver disorders such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) in an individual in need thereof, where treatment is understood to include reducing serum triglycerides.
[0127] In some embodiments, administration of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces the individual's total serum cholesterol. In some embodiments, administration of the combination may reduce the individual's total serum cholesterol when compared to administration of the SSAO inhibitor or the THR-β agonist as a monotherapy. In some embodiments, administration of the combination may reduce the individual's total serum cholesterol equivalent to administration of the SSAO inhibitor or the THR-β agonist as a monotherapy. Thus, the methods of treatment detailed herein, in some embodiments, include treating liver disorders such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) in an individual in need thereof, where treatment is understood to include reducing serum cholesterol.
[0128] In some embodiments, administration of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces serum alanine aminotransferase in an individual. In some embodiments, administration of the combination may reduce serum alanine aminotransferase in an individual compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. In some embodiments, administration of the combination may reduce serum alanine aminotransferase in an individual equivalent to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. Thus, the methods of treatment detailed herein, in some embodiments, include treating liver disorders such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) in an individual in need thereof, where treatment is understood to include reducing serum alanine aminotransferase.
[0129] In some embodiments, administration of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, reduces at least one or at least two of the individual's serum triglycerides, total cholesterol, and alanine aminotransferase. In some embodiments, administration of the combination may reduce at least one or at least two of the individual's serum triglycerides, total cholesterol, and alanine aminotransferase, when compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. In some embodiments, administration of the combination may reduce the individual's serum triglycerides, total cholesterol, and alanine aminotransferase. In some embodiments, administration of the combination may reduce the individual's serum triglycerides, total cholesterol, and alanine aminotransferase, when compared to administration of the SSAO inhibitor or the THR-β agonist in monotherapy. Thus, the methods of treatment detailed herein, in some embodiments, include treating liver disorders such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) in an individual in need of such treatment, wherein the treatment is understood to include reducing at least one or at least two of serum triglycerides, total cholesterol, and alanine aminotransferase.
[0130] In some embodiments, a method of reducing hepatitis in a patient in need thereof is provided, the method comprising administering to the patient a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist. In some embodiments, the method does not increase the patient's LDL-c level. In some embodiments, the method reduces the patient's LDL-c level. In some embodiments, the patient has a disease characterized by liver inflammation. In some embodiments, the patient has liver fibrosis. In some embodiments, the patient has NASH.
[0131] In some embodiments, a method is provided for treating a disease characterized by liver fibrosis in a patient in need of such treatment, the method comprising administering to the patient a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist. In some embodiments, the disease is associated with hepatitis. In some embodiments, the patient has NASH.
[0132] In some embodiments, there is provided a method of inhibiting expression of a gene involved in the production of collagen in the extracellular matrix of the liver in a patient in need of inhibition of gene expression, the method comprising administering to the patient a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharmaceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharmaceutically acceptable salt thereof), and optionally an FXR agonist. In some embodiments, the gene is a fibroblast gene. In some embodiments, the patient has liver fibrosis. In some embodiments, the patient has NASH.
[0133] Also provided herein is a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, for use in treating liver disorders, such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), in an individual in need thereof, using the methods as described herein.
[0134] Also provided herein is the use of a combination of an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof), and optionally an FXR agonist, for the manufacture of a medicament for the treatment of liver disorders, such as liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), in an individual in need thereof, using the methods as described herein.
[0135] In some of the foregoing embodiments, the SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) is administered orally. In some of the foregoing embodiments, the THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof) is administered orally. In some of the foregoing embodiments, the FXR agonist (such as a compound of formula (III) or a pharma- ceutically acceptable salt thereof) is administered orally.
[0136] In some embodiments of any of the foregoing, the compound of formula (I) is compound 1 or a tosylate salt thereof and the compound of formula (II) is compound 2 or a potassium salt thereof. In some such embodiments, the FXR agonist is a compound of formula (III), preferably compound 3, or a pharma- ceutically acceptable salt thereof.
[0137] Products and Kits The present disclosure further provides a product comprising the compound described herein, or its salt, the composition described herein, or one or more unit doses described herein in suitable packaging.In certain embodiments, the product is for use in any of the methods described herein.Suitable packaging (e.g., containers) are known in the art and include, for example, vials, containers, ampoules, bottles, jars, flexible packaging, etc.The product may be further sterilized and / or sealed.
[0138] The present disclosure further provides a kit for carrying out the method of the present disclosure, the present disclosure includes at least two compounds described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising a compound described herein, or a pharma- ceutically acceptable salt thereof. The kit may use any of the compounds disclosed herein, or a pharma- ceutically acceptable salt thereof. In some embodiments, the kit uses a SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof) described herein. The kit may be used for any one or more of the uses described herein, and therefore may contain instructions for treatment as described herein.
[0139] The kit generally includes suitable packaging. The kit may include one or more containers containing any compound described herein or a pharma- ceutically acceptable salt thereof. Each component may be packaged in a separate container, or several components may be combined in one container where cross-reactivity and shelf life are acceptable. In some embodiments, the kit includes a container containing an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof). In other embodiments, the kit includes a first container containing an SSAO inhibitor (such as a compound of formula (I) or a pharma- ceutically acceptable salt thereof) and a second container containing a THR-β agonist (such as a compound of formula (II) or a pharma- ceutically acceptable salt thereof).
[0140] The kit may be in unit dosage form, bulk packaging (e.g., multi-dose packaging) or sub-unit dose. For example, a kit may be provided that contains a sufficient dosage of a compound as disclosed herein, or a pharma- ceutically acceptable salt thereof, and / or an additional pharma- ceutical active compound useful for a disease detailed herein, to provide effective treatment of an individual for an extended period of time, such as, for example, 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. The kit may also include a plurality of unit doses of the compound and instructions for use, and may be packaged in an amount sufficient for storage and use in a pharmacy (e.g., a hospital pharmacy and a compounding pharmacy).
[0141] The kit may optionally include instructions, typically a set of written instructions, although electronic storage media (e.g., magnetic diskettes or optical disks) containing instructions are also acceptable, relating to the use of the component(s) according to the methods of the present disclosure. Instructions included in the kit generally include information regarding the components and their administration to an individual. EXAMPLES
[0142] The combination treatment provided herein can be tested by administering the combination of drugs to known mouse models and evaluating the results.The method of such testing can be adapted from known ones.See, for example, US Patent Publication No. 2015 / 0342943 (hereby incorporated by reference).
[0143] Example 1: Tolerability and Pharmacokinetics of Compound 1 in Healthy Human Subjects background Semicarbazide-sensitive amine oxidases (SSAOs) catalyze the catalysis of aldehydes, ammonium, and H of primary amines (e.g., methylamine, MMA). 2 O 2 SSAO contributes to non-alcoholic steatohepatitis (NASH) by increasing oxidative stress through deamination of SSAO to sucrose, as well as by recruiting inflammatory cells to the liver, exacerbating liver inflammation and damage. SSAO levels are elevated in NASH and correlate with fibrosis stage. Compound 1 is a selective covalent SSAO inhibitor that reduces liver inflammation and fibrosis in a rat model of NASH. A single ascending dose clinical trial of Compound 1 was conducted.
[0144] The compounds described herein may be obtained by the methods described in WO2018 / 028517, which is incorporated herein by reference in its entirety, particularly with respect to the methods of making the compounds detailed herein.
[0145] method Four groups of eight healthy participants were randomized in a 3:1 ratio to receive Compound 1 (tosylate) capsules or a matching placebo. Plasma levels of Compound 1 and PD biomarkers were determined pre- and at various time points post-dosing. SSAO inhibition was measured by plasma H after the addition of exogenous substrate (benzylamine). 2 O 2 The efficacy and safety of SSAO inhibitors was determined by measuring the relative reduction in its production. Endogenous methylamine (MMA) levels, which were predicted to increase upon SSAO inhibition, were measured in plasma. Safety was evaluated for 7 (± 3) days after dosing.
[0146] Plasma samples for determination of Compound 1 concentrations and SSAO activity were collected at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 (SSAO activity only), and 168 (SSAO activity only) hours after administration of a single dose of investigational drug (placebo or compound). Plasma PK parameters were determined by noncompartmental analysis. SSAO activity was measured by the increase in hydrogen peroxide (H 2 O 2 ) production levels. The percent change in total amine oxidase activity was determined compared to the corresponding pre-dose (baseline) samples.
[0147] Plasma SSAO-specific amine oxidase levels were determined using a kinetic-based assay essentially as previously described (Schilter et al.). 2 O 2 Before measuring production levels, endogenous monoamine oxidases A and B were inhibited by adding pargyline to the plasma samples. Maximal inhibition was defined by further treating pre-dose (baseline) samples with a high dose of Compound 1, and the percent change in SSAO-specific activity was calculated compared to the baseline samples.
[0148] result
[0149] Thirty-two healthy human participants (100% male, 63% black, 19% Asian, 13% white) were enrolled and administered a single oral dose of compound 1 (1, 3, 6, and 10 mg, n=6 each) or placebo (n=2). Plasma PK exposure of compound 1 increased in a more than dose-proportional manner between the 1 mg and 10 mg dose levels. The mean half-life of compound 1 ranged from 1 to 3 hours. We confirmed near complete inhibition of plasma SSAO activity in all dose cohorts at 4 hours post-dose, and detected continued suppression for up to 1 week after a single dose of compound 1. Maximum plasma MMA levels increased with compound 1. No clinically relevant adverse events or laboratory abnormalities were reported.
[0150] As shown in Table 1, doses of 1, 3, 6, and 10 mg of Compound 1 were all well tolerated. [Table 1]
[0151] A single dose of the tosylate salt of Compound 1 for SSAO was rapidly cleared from plasma and demonstrated plasma PK in a greater than dose-proportional manner between 1 and 10 mg.
[0152] As shown in Figure 1A and Figure 1B, a single dose of Compound 1 rapidly and potently reduced plasma amine oxidase activity in all subjects. Near-complete inhibition of SSAO-specific activity was observed 4 hours after dosing (Figure 1A and Figure 1B). Inhibition of plasma SSAO amine oxidase activity and dose-dependent increase in plasma MMA persisted for up to 1 week after a single dose of Compound 1, suggesting strong covalent target binding and supporting once-daily dosing despite the short plasma half-life (Figure 1A and Figure 1B).
[0153] Concentration of Compound 1 or placebo (C max ) was the IC of MAO-A and MAO-B at all dose levels. 50 The concentration was more than 800-fold lower than that of the control (Fig. 1C). [Table 2]
[0154] We observed a dose-dependent increase in methylamine, indicating strong plasma SSAO target binding across the dose range (Figure 1D).
[0155] conclusion Compound 1 was safe and well tolerated in healthy subjects administered single oral doses ranging from 1 mg to 10 mg. Compound 1 inhibited SSAO activity for up to 7 days after a single dose, suggesting that compound 1 may be effective in treating liver disease or disorders by selectively inhibiting SSAO. With only a single dose, some showed SSAO activity for the next 7 days, suggesting that daily dosing for 1 week may have a therapeutic effect over a 2-week period.
[0156] Example 2: Multiple Ascending Dose Study of Compound 1 in Healthy Human Subjects A multiple ascending dose clinical trial of Compound 1 was conducted. Three groups of eight healthy participants were randomized in a 3:1 ratio to Compound 1 or a matching placebo and received multiple doses once daily (QD) for 7 days (1 mg and 4 mg) or 14 days (10 mg). Plasma levels of Compound 1, as well as PD biomarkers (plasma amine oxidase activity and methylamine levels) were determined at various time points before and after dosing. Safety, including, among others, clinical laboratory values, vital signs, and ECG, was evaluated up to 14 days after the last dose, with no notable findings across subjects. All adverse events were judged to be mild (grade 1), with the exception of one moderate (grade 2) adverse event in the placebo treatment group. No subjects discontinued due to adverse events (see Table 3).
[0157] Plasma PK exposure of Compound 1 increased in a more than dose-proportional manner between dose groups on day 1, with significant accumulation observed at each dose level after multiple QD doses. Between the first and last days of dosing, the rate of accumulation decreased as dose increased. Steady state was achieved after 7 days in the highest dose cohort (10 mg). The half-life of Compound 1 increased with dose, consistent with saturable target-mediated clearance (see Figures 2A and 2B, Table 4).
[0158] On day 1, we observed almost complete inhibition of plasma SSAO activity in all dose cohorts (Figure 3A), which resulted in an increase in methylamine, an endogenous substrate of SSAO (Figure 3B). Plasma methylamine levels increased in a dose-proportional manner (Figure 3B). After multiple doses, we observed a further increase in plasma methylamine on the last day of Compound 1 administration (Figure 3C). Inhibition of total amine oxidase was incomplete due to the presence of plasma amine oxidases (e.g., MAO-A, MAO-B) that were not inhibited by Compound 1 (Figure 3D, E).
[0159] Compound 1 was safe and well tolerated in healthy subjects when administered at doses up to 10 mg (QD) for 14 days. Steady-state levels of compound 1 were achieved after 7 days of dosing, supporting the QD dosing regimen. Near-complete inhibition of plasma SSAO amine oxidase activity and dose-dependent increases in plasma methylamines persisted for up to 2 weeks after dosing was discontinued, suggesting that compound 1 administered daily for 2 weeks may exert a therapeutic effect for up to 2 weeks after dosing was discontinued.
[0160] [Table 3]
[0161] [Table 4]
[0162] Example 3: Activity and Pharmacokinetics of Compound of Formula (II) Exemplary compounds of formula (II) are provided in Table 5 below. Compound 2 is listed in the table as the second compound. The compounds described herein are disclosed in U.S. Application Publication No. 20200190064, the entire contents of which are incorporated by reference, specifically with respect to compounds of formula (II), such as Compound 2, or a pharma- ceutically acceptable salt or enantiomer thereof, as well as methods of making and using the foregoing.
[0163] [Table 5-1] [Table 5-2]
[0164] The compound of formula (II), in some embodiments, is selected from the group consisting of: 2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile, 2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile, 2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-methanophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile, 1-(3,5-dichloro-4-((7,7-dimethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentane[d]pyridazin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile, 2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile, 2-(3,5-dichloro-4-((5-chloro-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile, 2-(3,5-dichloro-4-((5-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile, 2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione, 2-(3,5-dichloro-4-((7,7-dimethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentyl[d]pyridazin-4-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione, and 2-(3,5-Dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)dione.
[0165] The compound of formula (II) has good agonist activity against THR-β receptors and has improved selectivity against THRα when compared to reference compounds in the literature ("Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia," Martha et al., Journal of Medicinal Chemistry, 2014, 3912-3923). The structure of the reference compound is: [ka] It is.
[0166] The test data are shown in Tables 6 and 7. [Table 6]
[0167] [Table 7]
[0168] Compared to the reference compounds, the exemplary compounds of formula (II) exhibited higher THR-β activity (<0.2 μM) and / or higher selectivity for THRα. The data also suggested that the compounds of formula (II) may activate downstream signals of thyroid hormone receptor beta.
[0169] Pharmacokinetic evaluation: Six healthy male SD rats (commercially available from Shanghai Sippr-Bk Laboratory Animal Co., Ltd.), with animal production license number: SCXK (Shanghai) 2008-0016, were divided into two groups with three rats in each group.
[0170] Drug preparation: A certain amount of drug was taken and added into 2% Klucel LF+0.1% Tween 80 aqueous solution to prepare a clear solution or homogeneous suspension.
[0171] Dosage: SD rats were fasted overnight and administered the drugs by intragastric injection at a dosage of 2 mg / kg and a dosage volume of 10 mL / kg, respectively.
[0172] Procedure: Compounds were administered to rats by intragastric infusion. At least 0.2mL of blood was collected from the tail vein at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, and 24 hours before and after dosing, and then the blood was placed in heparinized sample tubes and centrifuged at 4°C and 3500 rpm for 10 minutes to separate plasma. The heparinized sample tubes were then stored at -20°C, and the rats were allowed to eat food 2 hours after dosing.
[0173] Determination of the content of the tested compound in rat plasma after intragastric injection of drugs at different concentrations: Plasma samples were thawed at room temperature, 50 μL of each were taken and added to 130 μL of internal standard solution (1000 ng / mL, acetonitrile, tolbutamide), the mixture was rotated for about 1 minute, and then centrifuged at 4° C. and 13000 rpm for 10 minutes. 50 μL of the supernatant was taken and mixed with 100 μL of 50% acetonitrile water, then introduced for LC / MS / MS analysis.
[0174] The pharmacokinetic parameter results are shown in Table 8. [Table 8]
[0175] The data showed that the exemplary compounds demonstrated good pharmacokinetic absorption and significant pharmacokinetic advantages. Compared to the reference compounds, the exemplary compounds showed higher Cmax values and exposures at the same dose and preparation.
[0176] Example 4: Effects of Compound 2 on serum cholesterol and triglycerides SD rats were fed a high cholesterol diet for 2 weeks, during which serum cholesterol levels were increased approximately 4-fold. Single doses of 0.3-30 mpk of compound 2 or a single dose of 30 mpk of MGL-3196 were IP injected, and serum was analyzed for serum total cholesterol and triglycerides 24 hours after injection. Total cholesterol in serum was significantly reduced by 30-70% with compound 2 (Figure 4A). Compound 2 significantly reduced serum triglycerides by 30-80% from time 0 (Figure 4B).
[0177] Example 5: Effect of Compound 2 on mouse NASH model C57BL / 6J mice were fed a high-fat diet for 10 weeks to induce obesity (BW >38 g). Obese mice were then treated with 0.5 μl / g of 25% CCl to induce fibrosis. 4(formulated in olive oil) was injected intraperitoneally (ip) twice weekly for 4 weeks, and one group of normal BW mice was injected ip with olive oil twice weekly for 4 weeks to serve as healthy controls. During the same dosing period, obese mice were orally administered vehicle or various doses of Compound 2 once daily for 28 days. 4 On the day of administration of CCl 4 was administered 4 hours after compound or vehicle dosing. On day 27, all animals were fasted for approximately 16 hours before terminal euthanasia. On day 28, all animals were sacrificed and analyzed for various biological parameters. Total body weight, liver, heart and brain weights were measured, and changes in liver and heart weights were normalized using brain weight.
[0178] Compound 2 significantly reduced liver / brain weight without affecting total body weight or heart / brain weight (Figure 5). Liver histology was analyzed for the effect of Compound 2 on steatosis, inflammation and fibrosis. Compound 2 significantly reduced steatosis at all doses tested, showed a trend towards reduced inflammation, and significantly reduced liver fibrosis at 3 and 10 mpk (Figure 6). Compound 2 also significantly reduced serum total cholesterol, triglycerides and ALT at all doses tested (Figure 7).
[0179] Liver samples were taken for whole transcriptome analysis by RNA sequencing (RNAseq). Preparation and sequencing of RNAseq libraries (n=5 / group) was performed using Illumina standard protocols. Alignment of sequencing reads was performed using STAR aligner software, and read numbers were estimated using RSEM. Differentially expressed genes (compared to vehicle-treated NASH control mice) were determined using EdgeR software. Gene ontology analysis was performed using Advaita software with fold change and adjusted p-value cutoffs of >1.5 and <0.05, respectively. Gene ontology was obtained from the Gene Ontology Consortium database (April 26, 2019) (Ashburner et al., Gene ontology: Tool for the unification of biology. Nature Genetics 25(1):25-9(2000); Gene Ontology Consortium, Creating the Gene Ontology Resource: Design and Implementation. Genome Research 11:1425-1433(2001)). Compound 2 had a significant effect on the expression of genes associated with collagen extracellular matrix and hepatic stellate cell activation, mainly by reducing their expression levels compared to NASH control mice (Figure 8).
[0180] Example 6: Effect of pH and solubilizers on the solubility of Compound 2 The solubility of compound 2 (potassium salt) was evaluated at various pH levels. The solubility of compound 2 in aqueous solution was pH dependent and increased with pH as shown in Table 9. In the presence of a solubilizer (sodium lauryl sulfate, SLS), the solubility of compound 2 was further improved to 308 μg / mL after 24 hours at 25° C. in pH 10.0 buffer + 2 wt% SLS.
[0181] [Table 9]
[0182] Example 7: Formulation, pharmacokinetics, and food effect of Compound 2 in Beagle dogs To determine the effect of solubilizers on Compound 2 uptake, 50 mg (based on free acid) of Compound 2 was formulated into capsules with or without 5 wt% SLS (see Table 10) and administered to fasted beagle dogs pretreated with pentagastrin (6 μg / kg, administered by intramuscular injection 30±2 minutes prior to administration of Compound 2). Plasma concentrations of Compound 2 were measured over a 24 hour period (see FIG. 9). Formulations containing 5 wt% SLS significantly increased Compound 2 exposure (C max , AUC) to over 70% (see Table 11).
[0183] [Table 10]
[0184] [Table 11]
[0185] To determine the pH effect on PK performance, beagle dogs were divided into two groups (n=3 / group). In group 1, dogs were pretreated with pentagastrin (6 μg / kg, intramuscularly injected 30±2 minutes prior to administration of Compound 2). In group 2, dogs were pretreated with famotidine (2 tablets, 20 mg / tablet, orally administered 180±10 minutes prior to administration of Compound 2). Compound 2 (10 mg capsule, 5% SLS) was administered and plasma concentrations of Compound 2 were monitored for 24 hours as shown in Figure 10. Under the conditions tested, pH effects in dogs were minimal. To determine the effect of food on PK performance, beagle dogs were divided into two groups (n=3 / group). In the fasted group, dogs were fasted overnight and then fasted for 4 hours after dosing. In the fed group, dogs were fed a high fat meal 30 minutes prior to dosing. Plasma concentrations of Compound 2 were monitored for 24 hours. Compound 2 (10 mg capsule, 5% SLS) was administered and the plasma concentrations of Compound 2 were monitored for 24 hours as shown in Figure 11. Food intake significantly increased the Tmax was delayed but had no effect on plasma exposure.
[0186] Example 8: Single Ascending Dose Study of Compound 2 in Healthy Human Subjects method A single ascending dose clinical trial of Compound 2 (potassium salt) was conducted. Four groups of eight healthy participants were randomized to receive Compound 2 (3 mg, 10 mg, 30 mg, or 60 mg capsules) or matching placebo in a 3:1 ratio (n=6 active, n=2 placebo) administered during fasting state on study day 1. Plasma levels of Compound 2 and PD biomarkers were determined pre- and at various time points post-dose.
[0187] Adverse event (AE) monitoring, routine laboratory tests (including thyroid axis tests [free and total thyroid hormone triiodothyronine (T3), free and total thyroid hormone thyroxine (T4), thyroid stimulating hormone (TSH)], cardiac biomarkers [CK-MB, troponin I], and liver biochemistry), centralized vital signs, cardiac telemetry, and electrocardiograms were evaluated throughout the study. Plasma and urinary concentrations of Compound 2 were determined using a validated liquid chromatography-tandem mass spectrometry assay.
[0188] Plasma samples for Compound 2 concentration and PK sampling were collected pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after administration of a single dose of study drug (placebo or compound). Urine samples for Compound 2 concentration and PK sampling were collected pre-dose and at the following time points: 0-6 hours, 6-12 hours, 12-24 hours, and 24-48 hours. PK parameters were estimated by noncompartmental methods using Phoenix® WinNonlin® (Certara, LP, Princeton, NJ). Serum pharmacodynamic (PD) biomarkers apolipoprotein B (ApoB) and sex hormone binding globulin (SHBG) concentrations were measured using immunoassays, and serum lipids were determined using spectrophotometry.
[0189] PD sampling was performed pre-dose and 48 and 72 hours post-dose. Percent change from baseline in PD markers was calculated using an ANCOVA model with percent change from baseline as the dependent variable, treatment group as a fixed effect, and baseline as a covariate. Analyses used only actual data without imputation of missing data.
[0190] result Treatment-emergent adverse events monitoring All adverse events were mild or moderate in severity and largely unrelated to the study drug. No cardiac-related AEs (e.g., tachycardia, arrhythmia) were reported, and no significant changes were noted in vital signs or ECG parameters (see Table 12).
[0191] [Table 12]
[0192] Safety and Thyroid Axis Monitoring Heart rate remained stable and within the normal range over the 24 hours following dosing with Compound 2, showing a similar pattern to that seen in the placebo group (Figure 12). TSH, free T3, and free T4 levels remained within the normal range. No subjects experienced an increase in ALT more than 2-fold above the upper limit of normal (ULN), and no subjects had bilirubin levels above the normal range. In addition, no significant changes were observed in cardiac biomarkers (troponin I, CK-MB) or other clinical safety tests.
[0193] Pharmacokinetics Absorption of Compound 2 was less variable under fasting conditions (%CV≦33%). Exposure (AUC, C max ) was approximately dose proportional. The median half-life of compound 2 ranged from 13.8 to 17.3 hours, supporting once-daily dosing. Minimal renal excretion was observed at all doses. See Table 13, Figures 13A and 13B.
[0194] [Table 13]
[0195] Pharmacodynamics The mean percent changes in sex hormone binding globulin (SHBG) and apolipoprotein B (ApoB) on day 3 following a single dose of Compound 2 on study day 1 are shown in Figures 14A and 14B, respectively. The mean percent changes represent least squares means (LSM) and standard errors (SE) of the ANCOVA model. P values vs. placebo: * <0.05, ** <0.01, *** <0.001, **** <0.0001. A significant increase in SHBG was observed after a single dose of 10 mg or more of Compound 2 compared to placebo. A dose-dependent decrease in LDL-c, total cholesterol, and Apo-B was observed on day 3 after administration of a single dose of Compound 2, with similar results obtained on day 4. No significant changes were observed in triglyceride levels after a single dose of Compound 2 (see Table 14).
[0196] [Table 14-1] [Table 14-2]
[0197] conclusion Single ascending doses of Compound 2 up to 60 mg were generally safe and well tolerated, with linear and dose-proportional plasma exposure with low variability. Half-lives were greater than 13 hours at all single dose levels, supporting once-daily oral dosing. Renal excretion of unchanged Compound 2 was minimal, indicating that renal excretion is not the primary pathway.
[0198] Following a single dose of Compound 2, we observed significant dose-dependent effects on SHBG, ApoB, and LDL-c, indicating potential efficacy.* A threshold AUC of 1000 mg / mL achieved significant histological improvement in a mouse model of NASH) and in human subjects achieved sufficient exposure levels across all doses of Compound 2.
[0199] Safety, PK, and PD results support the continued development of compound 2 and indicate that it is well suited for co-formulation with other oral small molecule NASH agents as a once-daily oral fixed-dose combination.
[0200] Example 9: Multiple Ascending Dose Study of Compound 2 in Healthy Human Subjects A multiple ascending dose clinical trial of Compound 2 was conducted. Four groups of eight healthy participants were randomized to receive Compound 2 (1 mg, 3 mg, 6 mg, or 10 mg capsules) or matching placebo in a 3:1 ratio (n=6 active, n=2 placebo) once daily during 14 days of fasting state. Plasma levels of Compound 2 and PD biomarkers were determined pre- and at various time points post-dose.
[0201] Adverse event (AE) monitoring (Table 15), routine laboratory tests including thyroid axis tests [free and total thyroid hormone triiodothyronine (T3), free and total thyroid hormone thyroxine (T4), thyroid stimulating hormone (TSH)], cardiac biomarkers [CK-MB, troponin I], and liver biochemistry (Figures 15A-C, Figures 16A-C), central vital signs, cardiac telemetry, and electrocardiograms were evaluated throughout the study. Plasma and urinary concentrations of Compound 2 were determined using a validated liquid chromatography-tandem mass spectrometry assay.
[0202] Plasma samples for Compound 2 concentration and PK sampling were collected pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours after the first dose, pre-dose on days 3, 4, 5, 8, 11, and 13 of dosing, and pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after 14 days of study drug (placebo or compound) administration. (See Table 16, Figure 17). PK parameters were estimated by non-compartmental methods using Phoenix® WinNonlin® (Certara, LP, Princeton, NJ). Serum pharmacodynamic (PD) biomarkers apolipoprotein B (ApoB) and sex hormone binding globulin (SHBG) concentrations were measured using immunoassays, and serum lipids were determined using spectrophotometry.
[0203] PD sampling was also performed. Percent change from baseline in PD markers was calculated using an ANCOVA model with percent change from baseline as the dependent variable, treatment group as a fixed effect, and baseline as a covariate. Analysis used only actual data without imputation of missing data. PD data for study day 15 are shown in Figure 18. Results and Conclusions safety [Table 15]
[0204] Placebo or Compound 2 was administered at up to 10 mg once daily for 14 days and was generally well tolerated. No study or dose-escalation discontinuation criteria were met. All AEs were grade 1 and most were considered unrelated to study drug. All subjects randomized to Compound 2 completed the study without discontinuing study drug. Heart rate and blood pressure remained stable throughout the study. Free T4 decreased in a dose-dependent manner, but there was no apparent change in TSH or free T3, suggesting that peripheral thyroid hormone modulation lowered free T4 without altering T3 or TSH, as the changes in T4 were subclinical and not considered clinically significant.
[0205] Mean ALT values were similar between groups and not significantly different from placebo, and no treated subjects experienced an increase in ALT greater than or equal to 2-fold above the ULN. We observed a dose-dependent increase in GGT, although values remained below the ULN in treated patients. We observed a dose-dependent increase in total testosterone, but did not identify significant changes in free levels.
[0206] No significant changes were identified in ECGs, cardiac biomarkers, or other laboratory tests. Pharmacokinetics and Pharmacodynamics [Table 16]
[0207] Pharmacokinetic data demonstrated low PK variability and good oral bioavailability. Multiple doses of Compound 2 significantly and dose-dependently increased SHBG, even at doses as low as 3 mg QD. Reductions in total cholesterol, LDL-c, ApoB, and triglycerides were observed at all dose levels of Compound 2, with significant reductions observed at day 15 in the 10 mg dose cohort. HDL-c was not significantly changed by day 15. These results support the efficacy of low doses of Compound 2 once daily.
[0208] Example 10: Drug-drug interaction study with Compound 2 in healthy humans In vitro studies have shown that Compound 2 has potential for first-pass inhibition of organic anion transporting polypeptide (OATP) 1B1 / 1B3 and intestinal inhibition of breast cancer resistance protein (BCRP) transporter (OATP1B1 IC50=2.01 micromolar, OATP1B3 IC50=0.71 micromolar, BCRP IC50=9.37 micromolar). The effect of Compound 2 on the metabolism of co-administered rosuvastatin (ROS), an antihyperlipidemic drug and substrate of OATP and BCRP, in healthy participants is determined by administering Compound 2 and ROS as described in Table 17 in combination with PK sampling.
[0209] [Table 17]
[0210] In addition, compound 3 is an inhibitor of the intestinal expressed transporters P-glycoprotein (P-gp) and BCRP (P-gp IC50=3.92 micromolar, BCRP IC50=4.39 micromolar). Based on in vitro studies, inhibition of these transporters by compound 3 has the potential to increase the absorption of co-administered compound 2. Therefore, as described in Table 18, a drug-drug interaction (DDI) study is performed to evaluate the potential of compound 3 to enhance the absorption of compound 2 by inhibiting intestinal P-gp and BCRP.
[0211] [Table 18]
[0212] Example 11: Food effect on Compound 2 in healthy humans The effect of food on the uptake and pharmacokinetics of Compound 2 in healthy participants is determined by administering Compound 2 during fed and fasted states in combination with PK sampling, as described in Table 19.
[0213] [Table 19]
[0214] Participants will fast overnight (no food or liquids other than water for at least 10 hours prior to dosing). On day 9 of sequence A and day 1 of sequence B, a high-fat / high-calorie breakfast containing approximately 1000 kcal and 45%-55% fat will be provided 30 minutes prior to study drug administration. Study drug will be administered when participants finish their breakfast (100% consumed) or within 5 minutes of finishing it.
[0215] Thyroid axis safety monitoring and cardiovascular safety monitoring will be performed as described in the previous examples.
[0216] Example 12 Combination Therapy of Compound 1 and Compound 3 in a Rat Model of NASH Animal Handling: Upon arrival, rats were placed into a 2-week acclimation period during which they were accustomed to the animal facility staff and trained in the gavage procedure. After 2 weeks, animals were pre-fed with a CHDFD (choline-deficient high fat diet) for 4 weeks. Rats were then administered the test compound and NaNO 3 times per week. 2 Treatment with NaNO was started by ip injection and continued for another 8 weeks while rats continued on CDHFD. 2 was administered ip in PBS at 25 mg / kg three times a week (Monday, Wednesday, and Friday) for 8 weeks.
[0217] Final sacrifice: Half of the animals in each treatment group were sacrificed on day 84. The remaining half of the animals in each group were sacrificed the following day on day 85. On the day of sacrifice, the animals were fasted for 2 hours and administered the final treatment with each test substance. After the final compound treatment, the animals were deprived of food until sacrifice. All animals were sacrificed 4 hours after the last dose and liver samples were taken for further analysis.
[0218] Results: A choline-deficient high-fat diet (CDHFD) is commonly used to induce a NASH-like phenotype in rodent species. In addition, sodium nitrite (NaNO 2 Inducing liver fibrosis by intraperitoneal (IP) injection of NaNO can be used to model progressive NASH disease. 2 A NASH model was used to test the efficacy of Compound 3 alone and in combination with Compound 1. In this model, daily oral and three times weekly IP NaNO 2Prior to treatment, male Wistar rats were fed a CDHFD for 4 weeks to induce disease. After 8 weeks of dosing with compound 3 (3 mg / kg) and compound 1 (25 mg / kg) as single agents or in combination, liver tissue was processed for whole-transcriptome analysis by RNAseq to examine changes in gene expression associated with disease resolution. In NASH, resolution is a complex process involving liver infiltration of specialized cells of the immune system, including regulatory T cells (Tregs) and M2 macrophages. Tregs and M2 macrophages are involved in immunosuppression and reducing inflammation and appear to play a beneficial role in animal models of liver injury, including NASH. To examine the presence of these cells, we utilized RNAseq expression data to perform single-sample gene set enrichment analysis (ssGSEA) using cell type-specific gene expression signatures to quantify the relative levels of Treg and M2 macrophage infiltration into the liver (Figure 19). The combination of compound 3 (3 mg / kg) and compound 1 (25 mg / kg) showed significantly higher scores in both Treg and M2 macrophages compared to vehicle-treated NASH control animals. In contrast, animals treated with single agents were not significantly different from controls. These results were verified by analysis of individual markers of Treg and M2 macrophages, including Foxp3 (Treg), Ikzf2 (Treg), and Cd163 (M2 macrophages) (Figure 20). Only the combination of compound 3 (3 mg / kg) and compound 1 (25 mg / kg) showed significantly higher expression of markers associated with Treg and M2 macrophage cells. Taken together, these data suggest that the combination of the FXR agonist compound 3 and the SSAO inhibitor compound 1 resulted in increased expression of immune cell markers in the liver that are associated with the resolution of NASH. Considering the different mechanisms of action of compound 3 and compound 1, they may provide complementary benefits when used in combination and accelerate the resolution process of NASH.
[0219] These results demonstrate that the combination of an FXR agonist and an SSAO inhibitor is more effective than either of the two drugs administered alone.
[0220] Example 13: Differential gene expression of combination therapy of Compound 1 and Compound 3 in a rat model of NASH A study was conducted showing the beneficial effect of combining an FXR agonist and an SSAO inhibitor in a rat model of NASH.
[0221] Animal Handling: Upon arrival, rats were placed into a 2-week acclimation period during which they were accustomed to the animal facility staff and trained on the gavage procedure. After 2 weeks, animals were pre-fed with a choline-deficient high-fat diet (CDHFD) for 4 weeks to induce steatosis and a NASH-like disease phenotype. Rats were then treated with test compounds for an additional 8 weeks while on a CDHFD. Concomitant with compound treatment, rats were given sodium nitrite (NaNO 2 , 25 mg / kg dissolved in PBS) was administered by intraperitoneal (IP) injection three times a week to induce liver fibrosis.
[0222] Final sacrifice: Half of the animals in each treatment group were sacrificed on day 84. The remaining half of the animals in each group were sacrificed the following day on day 85. On the day of sacrifice, the animals were fasted for 2 hours and administered the final treatment with each test substance. After the final compound treatment, the animals were deprived of food until sacrifice. All animals were sacrificed 4 hours after the last dose and liver samples were taken for further analysis.
[0223] Sampling and analysis: Liver pieces were taken into RNAlater (Thermo Fisher Scientific Dreieich Germany) and stored at -20°C prior to RNA sequencing (RNAseq) at MedGenome Inc. RNAseq analysis was performed on liver tissue by Illumina sequencing using standard methods. Briefly, RNAseq libraries (n=5 / group) were generated using the Illumina Truseq stranded mRNA kit and sequencing was performed on a NovaSeq 6000 sequencer. Alignment was performed using the STAR (v2.7.3a) aligner and reads mapping to the ribosomal and mitochondrial genomes were removed prior to alignment. Raw read counts were estimated using HTSeq (v0.11.1) and normalized using DESeq2 (v2.22.2). Differentially expressed genes (DEGs) were determined using DESeq2 (R Bioconductor package).
[0224] result A choline-deficient high-fat diet (CDHFD) is commonly used to induce a NASH-like phenotype in rodent species. In addition, sodium nitrite (NaNO 2 Inducing liver fibrosis by intraperitoneal (IP) injection of NaNO can be used to model progressive NASH disease. 2 A NASH model was used to test the efficacy of Compound 3 alone and in combination with Compound 1. In this model, daily oral and three times weekly IP NaNO 2 Before treatment, male Wistar rats were fed CDHFD for 4 weeks to induce disease. After 8 weeks of dosing with Compound 3 (3 mg / kg) and Compound 1 (25 mg / kg) as single agents or in combination, liver tissue was processed for whole transcriptome analysis by RNAseq. Table 20 shows the CDHFD+NaNO treated with Compound 3 (3 mg / kg), Compound 1 (25 mg / kg), or a combination of Compound 3 (3 mg / kg) and Compound 1 (25 mg / kg). 2The total number and direction of change (i.e., up or down compared to vehicle control) of differentially expressed genes (DEGs) identified in rats are shown. Using an absolute fold change cutoff of ≥1.5-fold and an adjusted p-value of <0.01, 309 DEGs were identified in the compound 3 treatment group, 847 DEGs were identified in compound 1-treated animals, and 1351 DEGs were identified in the combination treatment group. These results suggest that the combination treatment had at least an additive effect on the total number of DEGs compared to the single-drug treatment groups.
[0225] Surprisingly, we observed a higher number of upregulated DEGs in the combined treatment group compared to the individual treatment groups. Figure 21 shows the number and overlap of DEGs (vs. vehicle NASH control) identified in each treatment group using absolute fold change and adjusted p-value cutoffs of ≧1.5 and <0.01, respectively.
[0226] [Table 20]
[0227] Next, we examined differential expression of genes associated with lipid metabolism and triglyceride accumulation previously described (Shepherd E, Karim S, Newsome P, and Lalor P., Inhibition of vascular adhesion protein-1 modifies hepatic steatosis in vitro and in vivo. World J Hepatol. 2020 12(11):931-948). Compound 1 treatment caused statistically significant changes in the expression of genes associated with lipid metabolism and fatty acid transport, including Vldlr, Fabp2, Vegfc, Ldlrap1, Ldlr, Ppargc1a, and Slc27a5 (Table 21, represented by asterisks). Of these, Vldlr, Fabp2, and Slc27a5 were changed by more than 1.5-fold (shown in bold). Upon treatment with Compound 3, only Fabp2 was significantly differentially expressed. Interestingly, the combination of Compound 3 and Compound 1 significantly increased DEGs related to lipid metabolism and fatty acid transport compared to either monotherapy group. Furthermore, several genes were differentially expressed by more than 1.5-fold compared to vehicle control, including Vldlr, Fabp2, Il1r2, Ppara, Ldlr, Ppargc1a, Rxra, and Slc27a5.
[0228] Taken together, these data suggest that the combination of FXR agonist compound 3 and SSAO inhibitor compound 1 significantly altered the expression of genes involved in lipid metabolism and fatty acid transport. Moreover, the pattern of gene expression changes is generally consistent with enhanced anti-adipose effects compared to treatment with compound 3 alone. Considering the different mechanisms of action of compound 3 and compound 1, they may provide complementary benefits when used in combination and accelerate the resolution process of NASH.
[0229] [Table 21]
[0230] CDHFD+NaNO2 Gene expression analysis (RNAseq) in rat liver. Log-1 expression of genes involved in lipid metabolism and fatty acid transport compared to vehicle control. 2 Fold change. A negative change (-) indicates a decrease in expression due to treatment compared to vehicle, and a positive change indicates an increase in gene expression compared to vehicle control. Absolute fold change values ≥ 1.5 fold (i.e., log 2 Fold changes ≥ 0.6 or ≤ -0.6) are indicated in bold. * p-value < 0.05.
[0231] Example 14: Differentially expressed genes (DEGs) of the combination therapy of Compound 2 and Compound 3 in a rat model of NASH C57BL / 6J mice were fed a high-fat diet for 10 weeks to induce obesity (BW >38 g). Obese mice were then treated with 0.5 μl / g of 25% CCl to induce fibrosis. 4 (formulated in olive oil) was injected intraperitoneally (ip) twice weekly for 4 weeks, and one group of normal BW mice was injected ip with olive oil twice weekly for 4 weeks to serve as healthy controls. During the same dosing period, obese mice were orally administered vehicle, Compound 3 or Compound 2 as single agents or in combination once daily for 28 days. 4On the dosing day, CCl4 was administered 4 hours after compound or vehicle dosing. On day 27, all animals were fasted for approximately 16 hours before terminal euthanasia. On day 28, all animals were sacrificed to collect liver samples for whole transcriptome analysis by RNA sequencing (RNAseq). RNAseq library (n=5 / group) preparation and sequencing were performed using Illumina standard protocols. Sequencing read alignment was performed using STAR aligner software, and read numbers were estimated using RSEM. Differentially expressed genes (compared to vehicle-treated NASH control mice) were determined using EdgeR software. Gene ontology analysis was performed using Advaita software with fold change and adjusted p-value cutoffs of >1.5 and <0.05, respectively. Gene ontologies were obtained from the Gene Ontology Consortium database (April 26, 2019) (Ashburner et al., Gene ontology: Tools for the unification of biology. Nature Genetics 25(1):25-9(2000); Gene Ontology Consortium, Creating the Gene Ontology Resource: Design and Implementation. Genome Research 11:1425-1433(2001)).
[0232] The direction of change (i.e., up or down) and total number of differentially expressed genes (DEGs) identified between vehicle-treated NASH controls and mice treated with compound 3 (3 mg / mg), compound 2 (1 mg / kg), or a combination of compound 3 (3 mg / kg) and compound 2 (1 mg / kg) are shown in Table 22. Using an absolute fold change cutoff of >1.5-fold and an adjusted p-value of <0.05, 617 DEGs were identified in compound 3-treated mice, 1113 DEGs were identified in compound 2-treated mice, and 1871 DEGs were identified in mice treated with a combination of compound 3 and compound 2. These results suggest that the combination treatment had at least an additive effect on the total number of DEGs compared to the arithmetic sum of the DEGs identified from each single-agent treatment group. The number of down-regulated DEGs (down-regulating DEGs) was higher in the combination treatment group compared to the arithmetic sum of the down-regulating DEGs from each single-agent treatment group. These results indicated that the combination of Compound 3 and Compound 2 resulted in a higher than expected number of DEGs compared to monotherapy, and this effect resulted in a higher than expected number of down-regulated DEGs.
[0233] [Table 22]
[0234] Example 14.1: Gene Ontology (GO) enrichment analysis Gene Ontology (GO) enrichment analysis was used to understand the potential biological consequences of the results in Table 22. To perform GO term enrichment analysis, the number of DEGs annotated (i.e., enrichment) for a particular term (i.e., biological process) was compared to the number of DEGs expected by chance alone. An overrepresentation approach was used to calculate the statistical significance (p-value) of observing at least a given number of DEGs, and the p-value was corrected for multiple comparisons.
[0235] Liver inflammation is a defining characteristic and key driver of NASH disease, and is primarily mediated by the overactivation and infiltration of leukocytes into the liver. Therapies that target inflammatory processes directly through anti-inflammatory mechanisms, or indirectly by reducing oxidative stress, for example by normalizing metabolic function and reducing fatty liver, have the potential to impact NASH disease. Table 23 shows the GO term enrichment analysis of DEGs associated with leukocyte-related biological processes. As shown in Table 23, only the combination of compound 3 and compound 2 showed statistically significant enrichment of DEGs associated with leukocyte-related biological processes. These results suggested that the combination of compound 3 and compound 2 had a much more significant effect on leukocyte-related biological processes than either monotherapy alone.
[0236] [Table 23]
[0237] Table 24 shows the GO term enrichment analysis of DEGs associated with immune and leukocyte-related biological processes that were uniquely enriched by the combination treatment as described in Example 14. [Table 24-1] [Table 24-2] [Table 24-3]
[0238] Implementation 14.2: Gene expression profile of selected biological processes Other biological processes related to NASH disease were also examined. Figure 22 shows the number of up- and down-regulated DEGs (vehicle NASH control vs. treatment) associated with different biological processes related to NASH and fibrosis, including leukocyte activation (GO:0045321), inflammatory response (GO:0006954), and collagen metabolism process (GO:0032963). For each biological process examined, the combination of compound 3 and compound 2 consistently showed a higher number of DEGs than expected compared to the single-drug treatment group. In addition, the combination of compound 3 and compound 2 showed a higher number of down-regulated DEGs than expected, which was expected based on the results of single-drug treatment.
[0239] Figure 23 shows the number and overlap of DEGs (vs. vehicle NASH control) identified in each treatment group using absolute fold change and adjusted p-value cutoffs of 1.5 or more and less than 0.05, respectively.The total number of differentially expressed genes is higher than expected when compound 3 and compound 2 are combined, with more than 800 unique to the combination, which is mainly driven by a higher number of down-regulated DEGs.Figure 24 shows the number and overlap of biological processes significantly enriched in treatment groups compared to NASH control.FDR adjusted p-values of less than 0.05 were used as the cutoff for statistical significance.
[0240] Example 14.3: Additive effect on mouse NASH model On the 28th day of treatment, animals were euthanized for sampling as described in Example 14. Analysis of cholesterol, triglycerides, and ALT was performed using a Hitachi 7180 clinical analyzer. Liver samples were processed for lipid quantification (colorimetric assay, SpectraMax 340PC384), histology, and RNA analysis. RNAseq library preparation (n=5 / group) and sequencing were performed using Illumina standard protocols. Sequencing read alignment was performed using STAR aligner, and read numbers were estimated using RSEM. Differentially expressed genes (DEGs) compared to NASH controls were determined using EdgeR. Gene ontology analysis was performed using Advaita software.
[0241] Figure 25 shows hepatic steatosis, inflammation, and fibrosis as quantified by histological analysis for the extent of steatosis, lobular inflammation, and fibrosis. Serum was collected at termination and analyzed for triglycerides (TG), total cholesterol (TC), and alanine aminotransferase (ALT), a biomarker of liver injury. Data are presented for individual animals (dots) and averages (dashed lines). ** p<0.01, *** p<0.001, **** p<0.0001 vs. NASH vehicle control (NASH). Statistics were determined by one-way ANOVA followed by Tukey. Combined treatment with Compound 1 and Compound 2 significantly improved multiple components of NASH, including steatosis, fibrosis, serum triglycerides, total cholesterol, and liver damage as measured by ALT.
[0242] Figure 26 shows the mean expression levels of genes associated with FXR and THRβ pathway activation. FXR and THRβ pathway genes were regulated in both the single agent and combination treatment groups.
[0243] FIG. 27 shows the average expression levels (count per million reads, CPM) of genes associated with collagen / fibrosis and inflammation pathways (determined by RNAseq). *p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 vs. vehicle (NASH) control. Error bars represent standard deviation (n=5). Combined treatment with Compound 1 and Compound 2 significantly reduced the expression of collagen / fibrosis genes and inflammatory genes, such as Col1a1, Col3a1, Mmp2, Lgals3, Cd68, and Ccr2.
[0244] conclusion Combined treatment with Compound 3 and Compound 2 resulted in gene expression changes consistent with on-target agonism of FXR and THR-β, respectively. Combined treatment with Compound 3 and Compound 2 significantly reduced the expression of fibrotic and inflammatory genes.
[0245] Gene ontology enrichment analysis identified the unexpected result that nearly 500 biological processes were uniquely enriched by the combination treatment of compound 3 and compound 2, including downregulation of processes related to immune processes (inflammation), leukocyte function, and collagen (including collagen production) (see Figure 22, Figure 27). Taken together, these data support the notion that the combination of compound 3 and compound 2 may provide additional benefits in NASH compared to monotherapy, such as reducing the inflammatory or fibrotic components of NASH more significantly than monotherapy alone. These effects are expected to reduce disease progression in addition to disease severity.
[0246] Example 15: Safety, Tolerability, and Efficacy of Combination Therapy in Patients with NASH A randomized, double-blind, placebo-controlled study will be conducted to evaluate the safety and efficacy of combination treatments, e.g., Compound 1 and Compound 2, or a combination of Compounds 1, 2, and 3. Subjects with NASH will be treated with a combination of an SSAO inhibitor and a THR-β agonist once daily for approximately 12-52 weeks. Liver fat will be monitored by MRI-PDFF, fibroinflammation will be monitored by corrected T1 (cT1) relaxation time, and serum-based non-invasive fibrosis or NASH markers, e.g., C3, TIMP-1, PIIINP, CK-18, and ALT, will be measured. Changes in serum lipid levels, e.g., LDL-c and other lipids, will also be monitored.
[0247] Example 16: Preparation of the potassium salt of compound 2 Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)hydrazinylidene)acetyl)carbamate (7.4 kg, 0.99-1.01 fold), potassium acetate (7.4 kg, 0.95-1.00 fold) and DMAc (41 kg, 5.6-6.0 fold) were charged to a 500 L GL reactor. The resulting mixture was held at 80-90 °C for 12-16 hours. The mixture was adjusted to 20-30 °C. A solution of KOH (0.85 kg, 0.11-0.17 fold) in process water (8 kg, 1.0-1.5 fold) was added at 20-30 °C for 1-2 hours. The mixture was stirred at 20-30 °C for 1-2 hours. Process water (39 kg, 5.0-5.5 fold) was added at 20-30°C for 4-6 hours. The mixture was stirred at 20-30°C for 2-3 hours. The resulting mixture was centrifuged by a stainless steel centrifuge. The wet cake was rinsed with process water twice (18+20 kg, 2-3 fold). The wet cake and process water (38 kg, 5.0-6.0 fold) were charged into a 500 L GL reactor. The mixture was stirred at 20-30°C for 2-3 hours. The resulting mixture was centrifuged by a stainless steel centrifuge. The wet cake was rinsed with process water twice (18+22 kg, 2-3 fold) and dried at 55-65°C under reduced pressure by a stainless steel dryer to obtain crude potassium salt of compound 2 (5.45 kg, purity: 98.4%, assay: 95.9%, yield: 72%).
[0248] Crude potassium salt of compound 2 (5.3 kg, 0.99-1.01x) and DMSO (43 kg, 6.0-8.0x) were charged to a 250GL reactor (R1). The resulting mixture was held at 40-50°C for 0.5-1 h to obtain a clear solution. Ethyl acetate (EA) (22 kg, 4.0-4.5x) was added at 40-50°C over 1-2 h. The resulting mixture was filtered through an in-line filter and transferred to a 250GL reactor (R2). R1 was rinsed with DMSO (1.8 kg, 0.2-0.5x) and the material was filtered through an in-line filter and transferred to R2. The temperature was adjusted to 40-50°C and EA (22 kg, 4.0-4.5x) was charged to R2 over 1-2 h at 40-50°C. Compound 2 seeds (0.010 kg, 0.001-0.002 fold) were charged into R2. The resulting mixture was stirred at 40-50 °C for 1-2 h. EA (67 kg, 12.0-13.0 fold) was charged into R2 at 40-50 °C for 12-15 h and stirred at 40-50 °C for 2-3 h. EA (27 kg, 1.0-5.0 fold) was charged into R2 at 40-50 °C for 2 h and stirred at 40-50 °C for 2-3 h. R2 was adjusted to 20-30 °C over 2 h and stirred at 20-30 °C for 4-6 h. The resulting mixture was filtered through a stainless steel filter dryer. The wet cake was rinsed twice with EA (16+14 kg, 2-3 fold). EA (36 kg, 6-7 fold) was charged into a stainless steel filter dryer. The temperature was adjusted to 20-30°C and stirred at 20-30°C for 2-3 hours. The resulting mixture was filtered through a stainless steel filter drier. The wet cake was rinsed with EA (16 kg, 2-3 times) and dried at 60-70°C under reduced pressure through a stainless steel filter drier. The material was sieved to obtain the purified potassium salt of compound 2 (4.16 kg, purity: 99.81%, assay: 97.6%, yield: 80%).
[0249] Example 17: method Part 1 of the two-part study was a double-blind, placebo-controlled study in 30 adults with a non-cirrhotic NASH phenotype, evaluating 10 mg of Compound 1 administered once daily (QD) for 12 weeks, followed by a treatment withdrawal evaluation at week 16 (Figure 28). The primary endpoint of the Part 1 interim analysis was safety as assessed by adverse events (AEs) and laboratory tests, with percent change from baseline (BL) in plasma VAP-1 activity being a secondary endpoint. Exploratory imaging and blood-based biomarkers of liver inflammation and fibrosis were also evaluated. Analysis of change from baseline (or percent change) used an ANCOVA model with change from baseline (or percent change) including treatment group as the dependent variable, randomization stratum as a fixed effect, and baseline as a covariate.
[0250] result Demographic and baseline characteristics of patients in the placebo and treatment groups were similar overall (Figure 29). Nearly all patients (28 / 30, 95% Compound 1 and 90% Placebo) completed Part 1 (Figure 30). Compound 1 (10 mg) was well tolerated with AE rates similar to placebo (Figure 31). All AEs were mild or moderate, and no serious AEs or trends in AEs or laboratory abnormalities were reported (Figures 32A and 32B). There was no significant change in cT1 from baseline to end of treatment (Figure 33). Compound 1 (10 mg) provided >98% inhibition of plasma VAP-1 activity in most subjects by week 2, with sustained suppression into week 12 (Figure 34). There were no statistically significant differences between placebo and Compound 1 10 mg in changes in BL cT1, liver fat percentage, liver enzymes, or cytokeratin-18. At week 12, significant differences from placebo were observed in the cell adhesion marker VCAM-1 and the liver fibrosis marker tissue inhibitor of metalloproteinase-1 (TIMP-1) (Figures 35 and 36). Cell adhesion markers including VCAM-1 and ICAM-1: VCAM-1 was decreased by 24.327 (20.5850) μg / L in the Compound 1 group and increased by a mean (±SE) of 63.450 (31.6861) μg / L in the placebo group at week 12 compared to BL (p=0.0245). ICAM-1 was decreased by a mean (±SE) of 34.85 (56.03) μg / L in the Compound 1 group and increased by a mean (±SE) of 7.46 (46.97) μg / L in the placebo group at week 8 compared to BL (p=0.0313). At week 12, TIMP-1 decreased by a mean (±SE) of 29.58 (9.26) ng / mL in the compound 1 group and increased by a mean (±SE) of 13.56 (14.22) ng / mL in the placebo group compared with BL (p<0.05).
[0251] conclusion Compound 1 was well tolerated with a safety profile similar to placebo in patients with baseline multiparametric MRI and LS values indicating NASH with at least stage 2 fibrosis. Compound 1 (10 mg) produced near complete inhibition of plasma VAP-1 activity, reduced levels of the liver fibrosis marker TIMP-1, and statistically significant reductions in the cell adhesion biomarkers ICAM-1 (week 8) and VCAM-1 (week 12) compared with placebo. After 12 weeks of treatment, no statistically significant differences were observed between Compound 1 and placebo for other markers of liver inflammation and injury.
[0252] Example 18. Clinical evaluation of Compound 2 in healthy subjects with elevated LDL-c levels Objective: To evaluate the overall safety and tolerability of multiple ascending doses of Compound 2 in healthy subjects with elevated LDL-c levels.
[0253] Secondary Objective: To evaluate the PK and PD of Compound 2 in healthy subjects with elevated LDL-c levels after multiple ascending doses of Compound 2.
[0254] Primary endpoints: Treatment-emergent adverse events (TEAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) monitoring
[0255] Secondary endpoints: Plasma PK parameters of compound 2, LDL-c and other lipid parameters, and PD markers of THR-β agonist target binding, including sex hormone binding globulin (SHBG).
[0256] Healthy volunteers with mildly elevated LDL-c were randomized 3:1 to Compound 2 (n=6) or placebo (n=2). Volunteers randomized to Compound 2 received multiple doses of 1, 3, 6, or 10 mg of Compound 2 once daily for 14 days in the MAD cohort of the study.
[0257] result Compound 2 was generally safe and well tolerated, with similar incidence of AEs across all Compound 2 treatment arms and placebo. All AEs were mild to moderate in severity and had no apparent dose-related relationship. All Compound 2 subjects completed the study without premature discontinuation, although one placebo subject (1 mg cohort) terminated the study early due to withdrawal of consent. No study or dose-escalation discontinuation criteria were met.
[0258] Liver biochemistry: ALT, AST, ALP, and total bilirubin values were generally similar across treatment groups. No subjects receiving Compound 2 had an increase in ALT ≥2-fold above the ULN. No evidence of DILI. Thyroid hormones: No symptoms of hyper / hypothyroidism. Mean TSH and free T3 values were generally similar, although highly variable across groups. Within the Compound 2 group, we observed a dose-dependent decrease in free T4, consistent with peripheral thyroid hormone regulation observed with other THR-□ agonists. Other clinical laboratory assessments (e.g., clinical chemistry, hematology) did not show clear trends.
[0259] Compound 2 was administered at 1, 3, 6, and 10 mg once daily for 14 days and was generally safe and well tolerated with no clinical signs or symptoms of hypo / hyperthyroidism or THR-α agonism. Compound 2 demonstrated dose-proportional PK with low variability and a half-life suitable for once-daily dosing. Compound 2 dose-dependently increased SHBG, a key marker of hepatic THR-β binding. Compound 2 resulted in significant reductions in circulating atherogenic lipid levels, including LDL-c, ApoB, total cholesterol, and triglycerides. Taken together, the PD data indicate that administration of compound 2 resulted in potent THR-β target binding in the liver.
[0260] All publications, including patents, patent applications, and scientific articles, mentioned in this specification are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, including patents, patent applications, or scientific articles, was specifically and individually indicated to be incorporated by reference.
[0261] Although the foregoing invention has been described in some detail by way of illustration and example for clarity of understanding, it will be apparent to those skilled in the art that certain minor changes and modifications will be implemented in light of the above teachings. Accordingly, the descriptions and examples should not be construed as limiting the scope of the invention.
[0262] Example 19: Effects of 12-week single and combined treatment with Compound 3 and Compound 2 on NAFLD activity scores including metabolic parameters, liver pathology and fibrosis stage in biopsy-confirmed male DIO-NASH mice
[0263] [Table 25]
[0264] Introduction Nonalcoholic steatohepatitis (NASH) is a disease manifested by hepatic inflammation and injury associated with hepatic steatosis, and combination therapies targeting multiple aspects of the disease may be required to achieve a high level of disease resolution. Small molecule agonists of the farnesoid X receptor (FXR), a nuclear hormone receptor that maintains metabolic pathway homeostasis, and the thyroid hormone receptor beta (THR-β), a nuclear hormone receptor that controls metabolic pathways complementary to FXR, are in development for the treatment of NASH. Compound 3, a nonsteroidal agonist of FXR, and compound 2, a liver-distribution selective agonist of THR-β, were evaluated alone and in combination in a diet-induced NASH mouse model.
[0265] Materials and Methods Animal handling and study design C57BL / 6JRj male mice (n=138) were fed a Gubra amylin NASH (GAN) diet (40% fat, 22% fructose, 2% cholesterol [D09100310, Research Diets]) or a lean chow diet for 35 weeks prior to the start of treatment. Prior to treatment, all animals underwent liver biopsy for histological confirmation (steatosis score ≥ 2 and fibrosis stage ≥ 1) and stratification using the Nonalcoholic Fatty Liver Disease (NAFLD) Activity Scoring (NAS) and Fibrosis Staging System. Diet-induced obese mice fed the GAN diet (DIO-GAN) were randomized into eight treatment groups (Table 25) based on the area percentage of picrosirius red (PSR) staining. DIO-GAN mice (n=16 / group) were treated (PO, QD) for 12 weeks with vehicle (0.5% HPMC + 0.2% Tween-80 in Tris buffer [50 mM, pH 8]), Compound 3 (10 mg / kg), Compound 2 (0.3 mg / kg [low], 2 mg / kg [medium], or 10 mg / kg [high]), or combination treatment of Compound 3 and Compound 2 (combination-low, combination-medium, or combination-high). Vehicle-administered and lean chow-fed controls served as healthy controls (n=10). Mice were maintained on their respective diets (GAN or lean chow) throughout the study period. Within-subject comparisons (pre- vs. post-treatment) were performed on histopathological scores of liver biopsies. Final quantitative endpoints included plasma / liver biochemistry, liver histomorphometry, and liver transcriptomics analysis by RNAseq.
[0266] [Table 26]
[0267] Processing and scoring of liver biopsies Formalin-fixed paraffin-embedded (FFPE) liver biopsies were prepared by placing liver samples in 10% neutral buffered formalin for approximately 24 hours, then transferring to 70% ethanol before storage at 4°C. FFPE were placed in a Histokinette and allowed to infiltrate before embedding into blocks. Biopsy tissue was then cut at 3 μm using a microtome, and sections were mounted on slides. Liver sections were stained with hematoxylin and eosin (H&E) to assess steatosis, inflammation, and ballooning, and with PSR to assess fibrosis. Slides were further processed to detect type I collagen (Col1a1), galectin-3 (Gal-3), and smooth muscle actin (α-SMA) protein expression by immunohistochemistry (IHC). For H&E staining, slides were incubated in Mayer's hematoxylin (Dako), washed in tap water, stained with eosin Y solution (Sigma-Aldrich), dehydrated, and coverslipped. For PSR, slides were incubated in Weigert's iron hematoxylin (Sigma-Aldrich), washed in tap water, stained with picrosirius red (Sigma-Aldrich), and washed twice in acid water. The slides were shaken to remove excess water, then the slides were dehydrated in ethanol, cleared in xylene, and coverslipped. NAS and fibrosis stage were scored as previously described (Kleiner et al. 2005). NAS represents the unweighted sum of steatosis, inflammation, and ballooning scores and ranges from 0 to 8 (Table 26), and fibrosis stage ranges from 0 (no fibrosis) to 4 (cirrhosis). For detection of Col1a1, Gal-3, and α-SMA, IHC was performed by standard procedures. Briefly, after antigen retrieval and blocking of endogenous peroxidase activity, slides were incubated with primary antibodies (Col1a1: Southern Biotech, Cat. No. 1310-01; Gal-3: Biolegend, Cat. No. 125402; α-SMA: Abcam, Cat. No. Ab124964). Primary antibodies were detected using polymeric HRP-linker antibody conjugates. Primary antibodies were visualized with DAB as a chromogen. Finally, sections were counterstained with hematoxylin and coverslipped.
[0268] [Table 27]
[0269] Analysis of liver enzymes, plasma lipids and CK18M30 Terminal blood was collected by cardiac puncture from mice anesthetized with isoflurane (2–3%), mixed with anticoagulant, and placed at 4 °C before centrifugation at 3000 × g for 10 min. Plasma supernatants were transferred to new tubes, immediately frozen on dry ice, and stored at -80 °C. Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL-c), and low-density lipoprotein (LDL-c) were measured on a Cobas c501 automated analyzer using commercial kits (Roche Diagnostics) according to the manufacturer's instructions. Cytokeratin 18M30 (CK18M30) was measured from plasma using a commercial ELISA kit (Cusabio) according to the manufacturer's instructions.
[0270] Analysis of liver lipids Liver samples were homogenized and heated (twice) at 90°C to extract TGs and TCs in 5% NP-40. Samples were centrifuged and TG and TC contents in the supernatants were measured on a Cobas c501 autoanalyzer using commercially available kits (Roche Diagnostics) according to the manufacturer's instructions.
[0271] Liver transcriptomic analysis by RNAseq Tissues were harvested, flash frozen in liquid nitrogen, and stored at -80°C until processing. RNA was isolated using the NucleoSpin kit (MACHEREY-NAGEL). A total of 10ng–1μg of purified RNA from each sample was used to generate cDNA libraries using the NEBNext Utra II Directional RNA Library Prep Kit for Illumina (New England Biolabs). The cDNA libraries were then sequenced on a NextSeq500 using the NextSeq500 / 550 High Output Kit V2 (Illumina). Sequencing data were aligned to the mouse genome using Spliced Transcripts Alignment to a Reference (STAR) software. Differentially expressed genes were identified using the R package DESeq2.
[0272] Analysis of trough plasma compound levels Final plasma samples were collected by cardiac puncture approximately 21-24 hours after the last dose of compound(s). Final plasma samples were analyzed by high-resolution LC-MS / MS using a Triple Quad6500+ instrument. 20 μL of plasma sample was mixed with 200 μL of internal standard (100 ng / mL labetalol + 100 ng / mL tolbutamide in acetonitrile), vortexed and centrifuged at 4,000 rpm for 15 minutes at 4°C. The supernatant (100 μL) was transferred to a sample plate, mixed with water (100 μL) and shaken (800 rpm) for 10 min, then injected (2 μL) onto a 1.7 μm, 2.1×50 mm ACQUITY UPLC BEH C18 column (Waters) at a flow rate of 0.6 mL / min using a gradient (Table 27) mobile phase of 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). Internal standard 1 (retention time: 0.87 min) and standard 2 (retention time: 0.96 min) were used to quantify compound 3 (retention time: 0.87 min) and compound 2 (retention time: 0.97 min), respectively. Internal standard (retention time: 0.76 min) was used to quantify the glucuronide metabolite of compound 3 (retention time: 0.77 min). For each analyte, a calibration curve (1-3000 ng / mL) was generated in a matrix of mouse plasma (pooled vehicle control).
[0273] [Table 28]
[0274] result Study Design Overview The Gubra amylin NASH model of diet-induced obesity (DIO-GAN) recapitulates many of the histopathological features of human NASH (Hansen 2020). The DIO-GAN model was used to evaluate the efficacy of the FXR agonist compound 3 and the THR-β agonist compound 2 as single agents and in combination. To induce NASH disease, C57BL / 6JRj mice were maintained on a diet high in fat, cholesterol, and fructose (GAN diet) for >35 weeks. Prior to therapeutic intervention, mice were biopsied to assess the severity of NASH disease and fibrosis, and mice with a steatosis score <2 and fibrosis stage <1 were excluded from the study. DIO-GAN mice were then randomized into eight treatment groups (n=16 / group) based on the percent area of picrosirius red (PSR) staining of pretreatment biopsies as well as the body fat tissue mass determined by whole-body magnetic resonance imaging (EchoMRI). In the monotherapy group, compound 3 was administered by oral gavage at a dose of 10 mg / kg once daily, while compound 2 was administered by oral gavage at dose levels of 0.3 (compound 2-low), 2 (compound 2-medium), or 10 (compound 2-high) mg / kg once daily. In the combination treatment group, a fixed dose level of compound 3 (10 mg / kg) was combined with low, medium, and high doses of compound 2 (combination-low, combination-medium, and combination-high, respectively). DIO-GAN mice administered vehicle by oral gavage once daily served as controls. Mice were treated for a total of 12 weeks and maintained on a GAN diet throughout the study. Lean mice (n=10) maintained on a normal chow diet throughout the study served as healthy controls.
[0275] Effect of treatment on body weight, food intake, and liver weight Treatment with Compound 3 alone and in combination with Compound 2 (combination-low, combination-medium and combination-high) reduced body weight during the study (Figure 46A). At the end of the study, Compound 3, combination-medium and combination-high treatment groups were significantly lower than the DIO-GAN vehicle control (Figure 46B). The reduction in body weight did not appear to be associated with a reduction in food intake (Figure 47). All treatment groups showed significant improvement in hepatomegaly (Figure 48A), with the greatest reduction in liver weight observed in the combination treatment groups (combination-medium and combination-high), but the change in spleen weight was not significant (Figure 48B).
[0276] Effect of treatment on body weight composition Body composition was determined by whole body EchoMRI at baseline (week -1) and week 11 of the study, and the relative levels of lean and adipose tissue were determined as a percentage of body weight. Baseline levels of lean and adipose tissue were well balanced across treatment groups (Figures 49A and 49B). Treatment with Compound 3 and in combination with Compound 2 reduced levels of adipose tissue at week 11 (Figure 50A), and a significant increase in relative lean tissue mass was observed in the Compound 3 and combination treatment groups (Figure 50B).
[0277] Effect of treatment on plasma and liver lipid levels Plasma total cholesterol was significantly reduced in all treatment groups (TC, FIG. 51A), with the greatest reduction observed in combination treatment (combination-medium and combination-high), and a similar trend was observed in liver TC (FIG. 51B). Reductions in plasma low- and high-density lipoprotein cholesterol (HDL-c and LDL-c, respectively) were consistent with the effects observed in TC. Combination treatment, as well as compound 3 and compound 2-high, significantly reduced plasma triglycerides (TG, FIG. 52A), with liver TG levels only significantly reduced in the combination-high group (FIG. 52B).
[0278] Effect of treatment on live enzymes Monotherapy with Compound 2 (low, medium, and high) significantly reduced ALT levels compared to the DIO-GAN vehicle control (Figure 53A), and ALT levels were not significantly reduced by combination treatment. AST levels showed a similar trend as ALT, but none of the treatment groups were significantly different from the DIO-GAN vehicle control (Figure 53B). ALP levels were not significantly different from the DIO-GAN vehicle control in any of the treatment groups, but ALP was numerically lower in the monotherapy groups (Compound 3, Compound 2-low, and Compound 2-medium) and higher in the combination-medium and combination-high treatment groups compared to the DIO-GAN vehicle control (Figure 54).
[0279] Liver histology NAFLD Activity Score (NAS) The histological effect of treatment was assessed using the NAFLD activity score (NAS). NAS is defined as the unweighted sum of steatosis, inflammation, and ballooning histological scores and can range from 0 to 8. The NAS of each animal was determined before treatment (baseline) and after 12 weeks of treatment at the end of the study. NAS was well balanced across treatment groups, with most mice having an NAS range of 5-6 at baseline (Figure 55A). After 12 weeks of treatment, NAS improved significantly in most treatment groups, with the greatest improvement seen with the combination treatment (Figure 55B). In the Compound 3 treatment group, 56% of animals showed an NAS improvement of 1 point or more, compared to 31%, 27%, and 62% in the Compound 2-low, Compound 2-medium, and Compound 2-high treatment groups, respectively (Table 28). Combination treatment was more effective, with 69%, 81%, and 100% of mice in the combination-low, combination-medium, and combination-high treatment groups, respectively, showing a 1-point or greater improvement in NAS. In addition, the magnitude of NAS improvement was greater in the combination treatment groups. 0% of mice in the compound 3 treatment group improved their NAS by more than 1 point, while 19%, 25%, and 43% of mice in the combination-low, combination-medium, and combination-high treatment groups, respectively, achieved a 2-point or greater improvement in NAS. These results were superior to those of the compound 2 monotherapy group, with 0%, 7%, and 25% of mice in the compound 2-low, compound 2-medium, and compound 2-high dose groups, respectively, achieving a 2-point or greater improvement in NAS.
[0280] [Table 29]
[0281] Steatosis NAS improvement was primarily driven by a significant reduction in steatosis (Table 29). In the Compound 3 group, 81% showed improvement in steatosis at the end of treatment, with the maximum improvement being 1 point. Compound 2 monotherapy groups confirmed a dose-dependent increase in the percentage of mice that showed improvement in steatosis, corresponding to 31%, 47%, and 81% of mice in the Compound 2-Low, Compound 2-Medium, and Compound 2-High dose groups, respectively. In each Compound 2 monotherapy group, one mouse (i.e., approximately 6%) showed a 2-point or greater improvement in steatosis. In contrast, 25%, 31%, and 71% of mice in the Combination-Low, Combination-Medium, and Combination-High treatment groups, respectively, showed a 2-point or greater improvement in steatosis. These effects were supported by quantitative liver histomorphometry, which showed a reduction in the percentage of hepatocytes containing lipid droplets (Figure 56A) and reduced liver lipid levels (Figure 56B), as well as a reduction in lipid droplet size (Figure 57).
[0282] [Table 30]
[0283] The combination of Compound 3 and Compound 2 resulted in significant improvement of fatty liver. Fatty liver was determined by histology at baseline and at the end of treatment for each mouse. Table 29 shows the percentage of mice in each treatment group that showed no change or improved steatosis score (1 point and 2 points or more reduction from baseline). Total represents the percentage of mice in each treatment group that showed at least 1 point improvement in steatosis from baseline.
[0284] Ballooning, inflammation, and fibrosis Hepatocyte ballooning, an indicator of apoptosis, was rarely observed and was not significantly altered by any of the treatments. CK18M30, a plasma biomarker associated with apoptosis, was also not significantly different between treatment groups and the DIO-GAN vehicle control (Figure 58). Lobular inflammation was not significantly improved by treatment, but improvements in inflammation scores were observed, albeit infrequently, in the Compound 2-Low, Compound 2-Med, and Compound 2-High treatment groups, as well as the Combination-Med combination group (Table 30). To further evaluate inflammation, protein expression Galectin-3 (Gal-3), a marker of inflammatory lymphocyte infiltration, was determined by immunohistochemistry (IHC) staining of liver. Treatment with Compound 3 alone and in combination with Compound 2 (Combination-Low) resulted in reduced Gal-3 expression levels in the liver compared to the DIO-GAN vehicle control (Figure 59A).
[0285] [Table 31]
[0286] Treatment did not significantly improve inflammation. Lobular inflammation was determined by histology at baseline and end of treatment. Table 30 shows the percentage of mice in each treatment group with worsening (increase of ≥1 point from baseline), no change, or improvement in lobular inflammation scores (decrease of ≥1 point from baseline).
[0287] Improvement in fibrosis stage was observed more frequently in the combination treatment group compared to the single agent groups, but did not reach significance (Table 31). Changes in Col1a1 protein expression, as determined by IHC staining of the liver, were not significantly different between treatment groups. A numerical decrease in α-SMA, a marker of hepatic stellate cell activation, was observed in the Compound 3, Compound 2-Low, and Compound 2-Mid treatment groups. A significant decrease was observed only in the Combination-Low treatment group (Figure 59B).
[0288] [Table 32]
[0289] Improvement of fibrosis was observed more frequently with combination treatment. Liver fibrosis stage was determined by histology at baseline and end of treatment. Table 31 shows the percentage of mice in each treatment group with worsening (increase of ≥1 stage from baseline), no change, or improvement in fibrosis (decrease of ≥1 stage from baseline).
[0290] Liver transcriptomic analysis by RNAseq
[0291] Final liver samples (n=10) from treatment groups were processed for transcriptomics analysis by RNAseq. Differentially expressed genes (DEGs) were identified compared to the DIO-GAN vehicle control. DEGs were identified in all treatment groups, with the lowest number of DEGs identified in the Compound 2-Low treatment group (987) and the highest number of DEGs identified in the Combination-High treatment group (3533). Comparing Compound 2-High to Combination-High showed that genes involved in energy and lipid metabolism were significantly differentially expressed with the combination treatment (Figure 60). This is shown by comparing the slope of the discrimination line of the fold change values (dotted line, slope = 1) to the linear regression line (solid line, slope = 0.55). Squalene epoxidase (Sqle) and 7-dehydrocholesterol reductase (Dhcr7), enzymes involved in cholesterol metabolism, were expressed at significantly higher levels in the combination group compared to the single drug treatments (Figures 61A and 61B). Hydroxymethylglutaryl-CoA synthase (Hmgcs1), a key enzyme in energy metabolism, also showed a similar expression pattern (Figure 61C). Stearoyl-CoA desaturase (Scd1), an enzyme involved in fatty acid metabolism, was decreased by compound 3 treatment and further decreased by combination treatment (Figure 61D).
[0292] Finally, we examined the expression of selected genes associated with fibrosis and inflammation, including type I collagen alpha 1 (Col1a1), actin alpha 2 smooth actin (Acta2), galectin 3 (Lgals3), and melanoma cell adhesion molecule (CD146). Overall, compound 3 alone and in combination with compound 2 significantly reduced the expression of these genes compared to the DIO-GAN vehicle control (Figure 62), and the combination treatment group was not significantly different from compound 3 treatment alone.
[0293] summary The mouse diet-induced obese Gubra-amylin NASH (DIO-GAN) model was used to evaluate the efficacy of compound 3 and compound 2 as single agents and in combination on metabolic and histopathological parameters of NASH and fibrosis. This model has been extensively characterized and recapitulates many aspects of human NASH without the use of hepatotoxic agents to induce disease (Hansen 2020). In this model, mice were maintained on a diet high in fat, cholesterol, and fructose (GAN diet) for over 35 weeks. Prior to therapeutic intervention, mice were biopsied to assess NAFLD activity score (NAS) and fibrosis severity by histology, and only mice with a baseline steatosis score >2 and fibrosis stage >1 were used in the study. Importantly, this preselection step ensured that only mice with significant NAFLD activity were used in the study. In addition, knowledge of baseline NAS allowed evaluation of treatment response not only compared to DIO-GAN vehicle control, but also compared to individual baseline values. DIO-GAN mice were treated with Compound 3 and Compound 2 alone and in combination for 12 weeks and maintained on the GAN diet throughout the study. To maximize the ability to identify potent additive treatment effects, mice were treated with a single dose level of Compound 3 alone or in combination with three dose levels of Compound 2 (low [0.3 mg / kg], medium [2 mg / kg], and high [10 mg / kg]).
[0294] The combination of Compound 3 and Compound 2 showed a greater reduction in NAS compared to the monotherapy, both in terms of the percentage of mice that showed a reduction in NAS and the magnitude of NAS improvement. The improvement in NAS was primarily driven by a greater reduction in steatosis, which was associated with a greater reduction in plasma and liver total cholesterol and triglycerides. The overall increased efficacy observed with the combination treatment did not appear to be due to the higher exposure of the individual drugs in the combination treatment group (Table 32). In addition, although changes in body weight may have contributed to the NAS improvement, the weight loss was similar between Compound 3 and the combination treatment groups (Combination-Low and Combination-Medium), suggesting that weight loss alone does not fully explain the increased anti-adipose activity of the combination treatment. Rather, the combination treatment had a greater effect on the expression of genes related to energy and lipid metabolism. These results suggest that the combination of Compound 3 and Compound 2 appears to have at least additive effects on these pathways, which may be responsible for the increased anti-adipose activity observed.
[0295] Histological improvement of inflammation and fibrosis was not significantly improved by treatment. However, we found evidence of fibrosis improvement, including an increase in the number of mice that showed fibrosis improvement with the combination. In addition, transcriptomics analysis identified key markers of fibrosis and inflammation that were reduced by combination treatment. The expression of these genes was also reduced by compound 3 treatment, suggesting that FXR agonism may be the main driver of the effect on fibrosis and inflammation at the gene expression level. In this case, FXR agonism may be considered complementary to the additional anti-adipose mechanism of THR-β agonism. These results, combined with the greater anti-adipose effect observed by combining compound 3 and compound 2, suggest that this combination may address multiple aspects of NASH disease.
[0296] References Kleiner DE,Brunt EM,Van Natta M,Behling C,Contos MJ,Cummings OW,Ferrell LD,Liu YC,Torbenson MS,Unalp-Arida A,Yeh M,McCullough AJ,Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology.2005 Jun;41(6):1313-21.
[0297] Hansen,HH,AEgidius,HM,Oro,D.et al.Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis.BMC Gastroenterol 20,210(2020).
[0298] supplement [Table 33]
[0299] Final plasma samples (i.e., trough), collected by cardiac puncture 21-24 hours after the last therapeutic dose, were analyzed by LC-MS / MS for the glucuronide metabolite of compound 3. Values represent the mean and standard deviation (SD). ND, not determined.
[0300] Example 20: A multicenter, randomized, double-blind, dose-ranging, placebo-controlled clinical trial will be conducted to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of orally administered Compound 1 in patients with presumed non-cirrhotic nonalcoholic steatohepatitis (NASH). Total study enrollment will be approximately 22 weeks, consisting of a 6-week screening period, a 12-week treatment period, and a 4-week follow-up period.
[0301] Approximately 80 adult patients with clinically or histologically diagnosed presumed non-cirrhotic NASH who met the study eligibility criteria were enrolled and randomized in an overall ratio of 2:1 to one of the three dose groups plus placebo across the two parts of the study. Eligibility criteria included overweight or obesity, presence of NASH by clinical diagnosis or biopsy, ALT ≥ 43U / L (men) or ≥ 28U / L (women), and MRI-cT1 liver inflammation > 800ms.
[0302] Part 1 of this study will evaluate 10mg of Compound 1, the highest dose tested in Example 2. In Example 2, this dose resulted in more than 90% inhibition of plasma VAP-1 / SSAO specific amine oxidase activity in healthy participants. Since NASH patients are expected to have higher baseline levels of VAP-1, the PD effect of Compound 1 in NASH patients may differ from healthy participants. Based on the evaluation of safety and PK at the 10mg dose, a higher dose of up to 20mg may be enrolled, and based on the observation of the strong PD effect of Compound 1 on plasma VAP-1 / SSAO activity in the 10mg cohort, a lower dose of 4mg may be enrolled, thus minimizing the number of patients exposed until the PK and PD effects of Compound 1 can be confirmed in Part 1 of the study.
[0303] In Part 1, approximately 30 patients will receive 10 mg of Compound 1 (n=20) or matching placebo (n=10) orally once daily for 12 weeks. Approximately 12 randomized patients will participate in centralized PK and PD collections after the first dose (Week 0 / Day 1), Week 6, and after the last dose of study drug (Week 12). Randomization will ensure that approximately 8 patients in the Compound 1 group and approximately 4 patients in the placebo group are assigned to the PK / PD substudy. Patients not participating in the PK / PD substudy will undergo trough PK / PD sampling only.
[0304] An interim analysis will be performed once all patients in Part 1 have completed the Week 6 evaluation. Interim PK and PD data will be evaluated. Blinded safety data will also be reviewed. If potent inhibition of VAP-1 / SSAO activity is observed and the effective PK in Part 1 suggests that lower doses may also result in potent inhibition of VAP-1 / SSAO activity, enrollment into Part 2 with 4 mg Compound 1 may begin. If safety data show that 10 mg Compound 1 is overall safe and well tolerated, and the effective PK in Part 1 indicates that the target exposure for the maximum 20 mg dose is an AUC of 5400 ng·hr / mL, 0-24hr and C of 768 ng / mL. max If the mean mean baseline score is predicted to be below the upper limit of 0.1 mg / kg, enrollment in Part 2 with Compound 1 at doses up to 20 mg may begin.
[0305] In Part 2, approximately 50 patients will receive 4 mg Compound 1 (n=20) and / or up to 20 mg Compound 1 (n=20) or matching placebo (n=10) orally once daily for 12 weeks. Approximately 15 randomized patients will participate in centralized PK and PD collections after the first dose (Week 0 / Day 1), Week 6, and after the last dose of study drug (Week 12). Randomization will ensure that approximately 6 patients at each Compound 1 dose level and approximately 3 patients in the placebo group are assigned to the PK / PD substudy. Patients not participating in the PK / PD substudy will undergo trough PK / PD sampling only.
[0306] PK / PD sub-study and trough PK / PD sampling Plasma samples will be collected to measure plasma concentrations of investigational drug and metabolites. Urine samples will be collected to measure urinary concentrations of investigational drug and metabolites. Patients not participating in the PK / PD substudy will only undergo trough PK sampling. Blood will also be collected for NASH / fibrosis markers (CK-18 (M30 and M65), PIIINP, TIMP-1, HA, PRO-C3, and C3M), and inflammatory markers (hs-CRP, IL-6, ICAM-1, and VCAM-1). The following exploratory fibrosis scores may also be calculated: FIB-4, enhanced liver fibrosis (ELF), and NAFLD. PRO-C3 / C3M ratios may be calculated. Patients will be monitored for adverse events.
[0307] Plasma and urine samples will be collected pre-dose from all patients on Days 1, 2, 15, 29, 43, 57, and 85. For patients in the PK / PD substudy: Plasma samples will be collected 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose on Days 1 (Week 0), 43 (Week 6), and 85 (Week 12), and a total urine collection will be performed 0-8 hours post-dose. Samples will be collected on Days 2 (Week 0), 44 (Week 6), and 96 (Week 12) (24 hours post-dose). Samples will be collected on Days 87 and 88 (48 and 72 hours post-dose on Week 12). Markers will be monitored including ALT, AST, ALP, and total bilirubin.
Claims
1. 1. A method for treating non-alcoholic steatohepatitis (NASH) in a patient in need of treatment comprising administering to the patient an SSAO inhibitor and a THR-β agonist, wherein the SSAO inhibitor has formula (1): 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof.
2. 2. The method of claim 1, wherein the SSAO inhibitor is a tosylate salt of the compound of formula (1).
3. The THR-β agonist is represented by the formula (II) 【Chemistry 2】 wherein R 1 is hydrogen, cyano, substituted or unsubstituted C 1~6 Alkyl, and substituted or unsubstituted C 3~6 cycloalkyl, the substituents being halogen atoms, hydroxy, and C 1~6 alkoxy; R 2 and R 3 is a halogen atom and a substituted or unsubstituted C 1~6 alkyl, each independently selected from the group consisting of halogen, hydroxy, and C 1~6 alkoxy; Ring A is a substituted or unsubstituted saturated or unsaturated C 5~10 Aliphatic ring, or substituted or unsubstituted C 5~10 An aromatic ring having a substituent selected from the group consisting of hydrogen, halogen, hydroxy, -OCF 3 , -NH 2 , -NHC 1~4 Alkyl, -N(C 1~4 Alkyl) 2 , -CONH 2 , -CONHC 1~4 Alkyl, -CON(C 1~4 Alkyl) 2 , -NHCOC 1~4 Alkyl, C 1~6 Alkyl, C 1~6 Alkoxy and C 3~6 one or more substances selected from the group consisting of cycloalkyl, where when two substituents are contained, the two substituents may form a ring structure together with the carbons to which they are attached; the halogen atoms are selected from the group consisting of F, Cl and Br; or a pharma- ceutically acceptable salt thereof.
4. The THR-β agonist is represented by the formula (IIa) 【Chemistry 3】 wherein R 1 ~R 3 is defined as set forth in claim 10, R 4 is hydrogen, halogen atom, hydroxy, -OCF 3 , -NH 2 , -NHC 1~4 Alkyl, -N(C 1~4 Alkyl) 2 , -CONH 2 , -CONHC 1~4 Alkyl, -CON(C 1~4 Alkyl) 2 , -NHCOC 1~4 Alkyl, C 1~6 Alkyl, C 1~6 Alkoxy and C 3~6 cycloalkyl; m is an integer ranging from 1 to 4; the halogen atoms are selected from the group consisting of F, Cl and Br; or a pharma- ceutically acceptable salt thereof.
5. R 4 is hydrogen, halogen atom, hydroxy, -OCF 3 , C 1~6 Alkyl, C 1~6 Alkoxy and C 3~6 cycloalkyl; The method according to claim 3 or 4, wherein m is an integer ranging from 1 to 3.
6. R 1 is hydrogen, cyano, and substituted or unsubstituted C 1~6 alkyl, the substituents being halogen atoms, hydroxy, and C 1~6 alkoxy; The method according to any one of claims 3 to 5, wherein the halogen atom is selected from the group consisting of F, Cl and Br.
7. The THR-β agonist has the formula (2): 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof.
8. The method of claim 7, wherein the THR-β agonist is a potassium salt of the compound of formula (2).
9. The method of any one of claims 1 to 8, wherein the SSAO inhibitor and the THR-β agonist are administered simultaneously.
10. The method of any one of claims 1 to 8, wherein the SSAO inhibitor and the THR-β agonist are administered sequentially.
11. The method of any one of claims 1 to 10, wherein the patient has liver fibrosis.
12. The method of any one of claims 1 to 11, wherein the patient also has diabetes.
13. The method of any one of claims 1 to 12, wherein the patient also has a cardiovascular disorder.
14. The method of any one of claims 1 to 13, wherein the duration of treatment is the remaining life span of the patient.
15. The method of any one of claims 1 to 14, wherein the SSAO inhibitor is administered once daily.
16. 16. The method of claim 15, wherein the SSAO inhibitor is administered to the patient at a dose of about 1 mg to about 40 mg per day.
17. The method of any one of claims 1 to 16, wherein the THR-β agonist is administered once daily.
18. 18. The method of claim 17, wherein the THR-β agonist is administered at a dose of about 0.5 mg to about 90 mg per day, and the THR-β agonist is the compound of formula (2) or a pharma- ceutically acceptable salt thereof.
19. 19. The method of any one of claims 1 to 18, wherein the SSAO inhibitor is administered at a dose of about 1 mg to about 40 mg per day, the THR-β agonist is administered at a dose of about 0.5 mg to about 90 mg per day, the SSAO inhibitor is a tosylate salt of the compound of formula (1), and the THR-β agonist is a compound of formula (2) or a pharmaceutically acceptable salt thereof.
20. 20. The method of any one of claims 1-19, wherein said administering comprises administering the SSAO inhibitor daily for a treatment period of one week or more.
21. 21. The method of any one of claims 1 to 20, wherein said administering comprises administering said THR-β agonist daily for a treatment period of one week or more.
22. 22. The method of any one of claims 1-21, wherein said administration reduces at least one of steatosis, liver inflammation, or liver fibrosis compared to administration of the SSAO inhibitor or the THR-β agonist monotherapy.
23. 23. The method of claim 22, wherein said administration reduces steatosis compared to administration of said SSAO inhibitor or said THR-β agonist as monotherapy.
24. 23. The method of claim 22, wherein said administration reduces liver inflammation as compared to administration of said SSAO inhibitor or said THR-β agonist as monotherapy.
25. 23. The method of claim 22, wherein said administration reduces liver fibrosis compared to administration of the SSAO inhibitor or the THR-β agonist as monotherapy.
26. 1. A method for reducing hepatitis in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an SSAO inhibitor and a therapeutically effective amount of a THR-β agonist, wherein the SSAO inhibitor has formula (1): 【Chemistry 5】 or a pharma- ceutically acceptable salt thereof, wherein the THR-β agonist is a compound of formula (2): 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof.
27. 27. The method of claim 26, wherein the SSAO inhibitor is a tosylate salt of the compound of formula (1) and the THR-β agonist is a potassium salt of the compound of formula (2).
28. 28. The method of claim 26 or 27, wherein each of the compound of formula (1), or a pharmaceutical salt thereof, and the compound of formula (2), or a pharmaceutical salt thereof, is administered to the patient once daily.
29. 1. A method for reducing hepatitis in a patient in need thereof without increasing LDL-c levels in said patient, comprising administering to said patient a therapeutically effective amount of an SSAO inhibitor and a therapeutically effective amount of a THR-β agonist, wherein said SSAO inhibitor has the formula (1): 【Chemistry 7】 or a pharma- ceutically acceptable salt thereof, wherein the THR-β agonist is a compound of formula (2): 【Chemistry 8】 or a pharma- ceutically acceptable salt thereof.
30. 30. The method of claim 29, which also reduces hepatic steatosis.
31. 31. The method of claim 29 or 30, which reduces LDL-c levels in a patient.
32. The method of any one of claims 29 to 31, wherein the SSAO inhibitor is a tosylate salt of the compound of formula (1) and the THR-β agonist is a potassium salt of the compound of formula (2).
33. 33. The method of any one of claims 29 to 32, wherein each of the compound of formula (1), or a pharmaceutical salt thereof, and the compound of formula (2), or a pharmaceutical salt thereof, is administered to the patient once daily.
34. 1. A fixed dose pharmaceutical composition for oral administration comprising a compound of formula (1): 【Chemistry 9】 or a pharma- ceutically acceptable salt thereof, and a compound of formula (2): 【Chemistry 10】 or a pharma- ceutically acceptable salt thereof.
35. 35. The fixed dose pharmaceutical combination of claim 34, wherein said SSAO inhibitor is the tosylate salt of said compound of formula (1) and said THR-β agonist is the potassium salt of said compound of formula (2).
36. 35. The fixed dose pharmaceutical composition of claim 33 or 34, wherein the composition comprises from about 1 mg to about 40 mg of the compound of formula (1), or a pharmaceutical salt thereof, and from about 0.5 mg to about 30 mg of the compound of formula (2), or a pharmaceutical salt thereof.
37. 35. The fixed dose pharmaceutical composition of claim 33 or 34, wherein the composition comprises from about 1 mg to about 40 mg of the compound of formula (1), or a pharmaceutical salt thereof, and from about 5 mg to about 20 mg of the compound of formula (2), or a pharmaceutical salt thereof.
